Catalyst pharmaceuticals

2023 ESG Report

Make a World of Difference

Published
June 2024

Table of Contents

Forward-looking Statement

This ESG Report contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2023 and its other filings with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found of Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

INTRODUCTION

About Catalyst Pharmaceuticals

Company Profile

Catalyst Pharmaceuticals , Inc. (“Catalyst”, “we”, “our”, or “Company”) is a biopharmaceutical company focused on in-licensing, commercializing, and developing innovative medicines to meaningfully improve the lives of patients with rare and difficult-to-treat diseases. Our Company was founded in 2002 and is headquartered in Coral Gables, Florida.

In 2023, our Company underwent transformational growth through product acquisitions, strategic partnerships, geographical expansion, and broader indications for our existing products. Our diversified product portfolio of groundbreaking medicines contributes to our ability to address critical unmet medical needs.

Catalyst is dedicated to providing first-in-class medicines to patients living with rare and other difficult-to-treat diseases, with its diverse portfolio of commercial products. In 2023, our product commercialization rights expanded from four countries (United States (“U.S.”), Canada, Mexico, and Japan) to include all of Central and South America, Australia, and select additional countries in Asia. Our flagship product FIRDAPSE® (amifampridine) Tablets 10 mg, is the only evidence-based, U.S. Food and Drug Administration (“FDA”)-approved treatment of Lambert-Eaton Myasthenic Syndrome (“LEMS”). In 2023, we acquired the U.S. rights to FYCOMPA® (perampanel), which is the first and only FDA-approved non-competitive AMPA receptor antagonist used to treat seizures in epilepsy patients. We further expanded our portfolio in 2023 by obtaining an exclusive North American licensing agreement for AGAMREE®, an innovative corticosteroid for the treatment of Duchenne muscular dystrophy (“DMD”).

This track record of successfully bringing life-changing therapies to market and enhancing patient care and outcomes is also reflected as part of our strategic growth efforts, with revenue growth of 85.9% year-over-year with 2023 revenues of $398.2 million[1]. Additionally, our growth is equally reflected in our workforce, as we have increased our headcount from 75 full-time employees in 2022 to 164 full-time employees in 2023.[2]

1. Q4 2023 financial results
2. Data as of 12/31/2023

Company Profile

HQ: Coral Gables, FL	2002 Founded	2006 Completed IPO	164 Full-time Employees[3]
USA CAN MEX JPN Commercialization rights in 4 countries		4 Diseases Treated with CPRX Products[4]	

>250,000

Number of Patients Treated in 2023

OUR IMPACT, AWARDS AND RECOGNITIONS:

- **Ranked 4 out of 100** on Forbes 2024 List of America's Most Successful Small-Cap Companies
- **Achieved "BBB" MSCI rating**, a significant upgrade from our "CCC" rating in September 2021
- **Considered "Low Risk"** with an 18.2 score for Sustainalytics

Forbes 2024
AMERICA'S MOST SUCCESSFUL SMALL COMPANIES

INDUSTRY ASSOCIATION MEMBERSHIPS:

PPSWG

The Pharmaceutical Product Stewardship Work Group (PPSWG)

GS1

RX-360

The International Pharmaceutical Supply Chain Consortium

3. Data as of 12/31/2023
4. Catalyst products used to treat LEMS, DMD, and two forms of epilepsy including partial onset seizures (that may or may not develop into general seizures) and primary generalized tonic-clonic (PGTC) seizures (in conjunction with other medications).



Our Mission, Strategic Pillars, and Values

To fulfill our mission, Catalyst combines innovative medicines with unmatched patient care to enhance the lives of patients suffering from rare and difficult-to-treat diseases, often without any therapeutic options. With an unwavering patient focus embedded in everything we do, we are driven to bring innovative, groundbreaking medications to market, with the hope of making a meaningful impact on patients, their caregivers, and their families who are all affected by these conditions. We are diligent in ensuring that our commitment to patient accessibility, product quality and safety, and drug affordability remains steadfast as our business evolves and product portfolio expands.

Our mission and our Company's broader business decisions continue to be guided by three core values: **Passion**, **Trust**, and **Integrity**:

Passion is our commitment to engage, energize, and inspire others and ourselves.

Trust is our commitment to live an authentic life, with sincerity and honesty in all endeavors.

Integrity is our commitment to the highest ethical standards, to lead with principles and to expect the very best from our employees and our company.

To supplement our core values, we operate our business around four key pillars:

1. **Commercial Excellence:** We have a proven track record of commercializing innovative medicines with a supreme focus on patient care and access, and we will continue to maintain the highest level of operational excellence to support strong performance across our product portfolio.

2. **Portfolio Expansion:** We have demonstrated success acquiring and integrating impactful complementary assets to drive strong and sustained growth, and we will continue to make strategic investments aimed at expanding and diversifying our portfolio.

3. **Strategic Partnerships and Maximizing Our Existing Products:** Our ex-U.S. partnerships in key markets are enabling growth of our global footprint, and we are focused on maximizing the value of our existing portfolio through thoughtful lifecycle management and continued geographical expansion via partners.

4. **Financial Discipline:** Our positive cash flow and strong balance sheet enable continued execution against our strategic priorities, and we plan to continue delivering the financial rigor that our shareholders have come to expect.

CEO Letter

Since stepping into the role of CEO at the start of 2024, and following eight years as a member of the Board of Directors, I remain inspired by Catalyst's dedication to improving the lives of patients living with rare and other difficult-to-treat diseases, putting patient care and access at the forefront of all that we do. I am proud of our progression to integrate sustainability practices into our business strategy and realize the value this provides for our shareholders. As such, Catalyst will continue to operate with a patient-centric focus in which we combine groundbreaking medicines with an unmatched focus on the patient communities we serve and a commitment to championing sustainable business operations.

Our business underwent a significant transformation in 2023 with the acquisitions of FYCOMPA® and AGAMREE®. We expanded our reach into new therapeutic areas, while also broadening the impact of our therapies across more patient populations. Just as we have expanded our reach into new therapeutic areas, our strategic partnerships have expanded our reach into new areas. For a few years, LEMS patients in Canada have had access to FIRDAPSE®, but now we are working with our partner in Japan to similarly expand access to FIRDAPSE® to LEMS patients in 2025. Both our product expansion and our geographic expansion demonstrate our desire and ability to continue to address important unmet needs for our innovative therapies and build a commercial presence globally.

For FIRDAPSE®, we are prioritizing physician education and testing for LEMS, particularly in the small cell lung cancer ("SCLC") community, as this condition is often identified concurrent with a cancer diagnosis. As part of our ongoing efforts to facilitate earlier identification of patients who may be eligible for FIRDAPSE®, Catalyst has reached out to over 20,000 neurologists and 16,000 oncologists over the past year who are potential LEMS prescribers or who may treat LEMS patients with SCLC to raise awareness of LEMS and how to diagnose it.

Our successful U.S. commercialization of FIRDAPSE®, the only evidence-based FDA-approved treatment for LEMS, underscores the strength of our commercial capabilities, guided by our unwavering ethical principles and dedication to operational excellence. As we ramp up our commercialization partnerships and collaborations around the world, we remain committed to ensuring that all patients in need of our treatments have uninterrupted access to safe and affordable medications. Our Catalyst Pathways® patient services program continues to aim to set the gold-standard for patient services, with comprehensive services that aim to provide educational resources and insurance information, comprehensive one-on-one support, and access to financial assistance programs. Having been traditionally tailored for FIRDAPSE® patients, we successfully integrated AGAMREE® into Catalyst Pathways® in conjunction with the product's U.S. commercial availability. This integration emphasizes our commitment to delivering the highest possible level of services to the rare disease patient communities we serve. In addition to expanding our product portfolio, Catalyst has grown its workforce to support the expansion of our commercial activities and enhance our ability to meet the needs of patients, physicians, and families. Our working culture reflects our patient-centric and people-first mindset, and we are proud of our employees for fulfilling our mission and living out our core values of Passion, Trust, and Integrity.

We are pleased to present our 2023 ESG Report, detailing our progress over the past year, and highlighting our commitment to conducting our business in a way that drives long-term, sustainable growth. We are proud of our progress to mature our ESG program throughout the past year, and I look forward to sharing future updates that demonstrate our steadfast commitment to our patients, their families, and all stakeholders.

Sincerely,

Richard Daly
President and Chief Executive Officer

About this Report

Catalyst Pharmaceuticals is pleased to publish our 2023 ESG Report, which outlines our practices, policies, and performance on relevant ESG issues during the fiscal year ending December 31, 2023. All data and discussion of performance included herein reflect Catalyst's operations in fiscal year 2023 unless noted otherwise.

Our 2023 ESG Report reflects Catalyst's up-to-date activities to address relevant ESG topics, which have been identified as those that are most material to Catalyst's operations and value chain. This report and the disclosures herein align with the Sustainable Accounting Standards Board ("SASB"), Global Reporting Initiative ("GRI"), and United Nations Sustainable Development Goals ("UN SDGs") frameworks. Catalyst is committed to improving the lives of our patients, and our approach to embedding ESG risk management principles and performance considerations in our daily operations is underpinned by engagement with all stakeholders including our employees, patients, physicians, suppliers, and shareholders. To provide our stakeholders with the utmost transparency, where possible, we deploy both qualitative proof-points and quantitative key performance indicators ("KPIs").

This 2023 ESG Report cannot be considered a substitute for any material information included or disclosed in Catalyst's SEC filings such as, but not limited to, our Form 10-K, Form 10-Q, and Form 8-K. Any references to "material" or "materiality" in this report or related website content are not intended to have the same meaning as in the context of financial statements or financial reporting or as defined by the securities laws of the U.S. For purposes of this report, we follow the GRI definition of materiality for our ESG materiality assessment.

To provide feedback or submit questions regarding this report or Catalyst's ESG initiatives, please contact info@catalystpharma.com.

Our Approach to ESG

Materiality Assessment

At Catalyst, we continue to advance our ESG program by prioritizing the ESG matters that are most material to our business, as well as those in which we can have the largest impact. In 2022, we conducted a materiality assessment to identify the most material ESG matters to our Company. The process was guided by an experienced third-party ESG advisor, and informed by market research, recommended disclosures from SASB and TCFD, rating agencies, direct stakeholder engagement, and cross-segment discussion within our Company.

Our previously identified material topics continue to remain pertinent to Catalyst's current processes and are considered in our current business strategy. We also make an effort to ensure these priorities are communicated throughout our business as our portfolio expands to continue deriving value and providing transparency to various stakeholder groups, including our patients and investors.

Environment	Description
Emissions and Energy Management	Management/oversight, tracking, and reduction of energy consumption and scope 1-3 GHG emissions.
Waste Management	Management of hazardous and toxic waste and the ability to minimize waste.
Climate Strategy	Processes, practices, and goals that enable the Company to reduce its environmental impacts, improve transparency and public disclosures, and increase its operating efficiency.
Water and Effluents	Management of water usage, including the ability to reuse and recycle.

Social	Description
Access to Healthcare	Initiatives, pricing practices, and strategies to eliminate unjust, avoidable, and unnecessary barriers to accessible healthcare, thus creating a sustainable healthcare system in which every person has a fair opportunity to access care and medicines.
Product Quality and Safety	The efficacy of quality control, product testing, and resale processes, protocols, and efforts to preemptively address product defects and ensure products remain safe for patient use.
Human Rights	Efforts to respect, protect, and fulfill human rights and fundamental freedoms across our own and suppliers' operations, including compliance with applicable laws and internal standards.
Community Involvement	The frequency, focus, and efficacy of Company-sponsored volunteerism and community engagement efforts to strengthen local communities, support overall culture, and empower employees to support causes important to them and/or the organization.
Patient Safety	The processes and practices in place to prevent and reduce risks, errors, and harm to patients during provision of healthcare and clinical trials, ensuring positive health outcomes.
Human Capital	Management of our workforce through minimizing turnover and maximizing retention as well as successfully attracting and developing the level of talent and expertise needed to support our strategic growth plans. Additionally, this includes oversight, management, and transparent reporting of employees' health and safety with the goal of providing an overall incident-free workplace.
Supply Chain Management	Efforts to monitor, assess, and proactively mitigate risks – including those related to environmental and social matters – stemming from the supply chain to ensure resiliency in the event of supply chain disruptions.

Social	Description
Diversity, Equity, and Inclusion	Diversity, equity, and inclusion performance, programs, initiatives, and ability to track and report improvement over time to support an inclusive, diverse, and equitable organization.
Product Innovation	The ability to develop new, safe, and sustainable products to improve patient health.

Governance	Description
Executive Incentives	Compensation plan for executives and associated metrics including those linked to reaching ESG targets set by the Company in order to promote sustainability.
Board Composition	Our Board of Directors' independence, expertise, size, and general structure as well as demographic characteristics, such as gender, race, ethnicity, and age that will provide for diverse backgrounds, viewpoints, and perspectives.
Business Ethics and Transparency	Formalized processes, policies, and oversight structures in place to ensure the Company and its employees are operating ethically, in line with applicable regulations, and that reporting of unethical behavior is encouraged.
Shareholder Rights	Practices related to shareholder engagement and the provision of voting rights, rights to call special meetings, appoint directors, and act by written consent.
Regulatory Preparedness	Proactive monitoring and tracking of potential regulatory changes and the Company's ability to adhere to any new legislation or regulation which may impact our business activities or create new reporting obligations.
Data Privacy and Security	Practices, compliance procedures, and oversight mechanisms in place to identify and limit illegal and unethical use of personal employee, patient, and vendor data.
Ethical Marketing	Formal practices, policies, and oversight mechanisms to ensure products are accurately and transparently marketed and advertised to customers and business partners.
ESG Oversight	Explicit Board and management-level oversight of and responsibility for ESG initiatives, along with the efficacy of oversight structures in place to drive change, advance the Company's ESG strategy, and achieve our ESG targets.

ESG Oversight & Business Ethics

ESG Oversight

The Catalyst Board of Directors ("Board") is responsible for ESG oversight. Each Board committee is delegated ESG-related responsibilities that address our ESG strategy, initiatives, and policies, and are relevant to their other duties:

COMPENSATION COMMITTEE

Responsible for designing, evaluating, and approving compensation plans, policies, and programs, and ensuring fair and equitable pay for all employees.

AUDIT COMMITTEE

Manages and facilitates the legal and regulatory compliance and risk management function, ensuring risks associated with financial reporting, operations, and ESG are addressed with properly functioning controls.

CORPORATE GOVERNANCE AND NOMINATING COMMITTEE

Identifies and selects Board members, ensuring each member supports ESG objectives and is capable of performing delegated ESG oversight responsibilities, develops corporate governance guidelines, and oversees periodic evaluations of the Board.

Our **Corporate Responsibility Steering Committee** is comprised of our Chief Legal and Compliance Officer and Vice President of Investor Relations. This Committee is responsible for assessing Catalyst's ESG program, addressing disclosure gaps, and establishing policies and practices to set ESG goals, monitor activities, and manage the processes for addressing issues in these areas. As the Company grows, this committee is dedicated to ensuring Catalyst's ESG program is relevant and meaningfully incorporated into our broader business strategy. This Committee regularly engages the Board, relevant committees, executives, and cross-functional stakeholders to report ESG progress and continue maturing our program.

ESG Oversight Responsibilities Across Our Organization



Employees within **cross-functional departments** at Catalyst have ESG responsibilities integrated into their roles, including tracking data and assessing ESG activities related to their roles:

Our **Patient Advocacy team** leads activities, performs research, and engages in external communication with advocacy organizations and our communities. They work alongside our Patient Services team, which manages Catalyst Pathways®, to support our patients throughout their treatment journey.

Our **Manufacturing and Supply Chain team** manages our relationships with contract manufacturers, including gathering ESG data from manufacturers and ensuring that drug safety testing and quality standards are met.

Our **Human Resources team** manages diversity, equity, and inclusion, as well as other employee engagement-related activities related to employee recruitment, development, and retention.

Our **Quality team** manages information related to product quality and quality outcomes, ensuring best-in-class quality control processes for our products.

Business Ethics & Transparency

Catalyst is committed to conducting business according to the highest ethical standards. We prioritize transparency and integrity in all that we do. Our ethical principles are outlined in our Code of Business Conduct and Ethics, which guides all employees and Board Members to abide by the following principles:

- Promote compliance with all relevant governmental laws, rules, and regulations;
- Promote honest and ethical conduct, including the handling of actual or apparent conflicts of interest;
- Promote full, fair, accurate, timely, and clear disclosures in all Company reports, public filings, and communications made by Catalyst;
- Promote the protection of Catalyst's assets;
- Promote fair practices within the marketplace and deter wrongdoing; and
- Provide for timely reporting of all potential or actual violations of the Code.

ALL CATALYST EMPLOYEES ARE REQUIRED TO UNDERSTAND, COMPLY WITH, AND REPORT ANY SUSPECTED VIOLATIONS OF THE CODE OF BUSINESS CONDUCT AND ETHICS.

Employee Training

Catalyst administers periodic training on our Code of Business Conduct and Ethics for all employees. We require our Medical Affairs and Commercial employees to participate in an initial training on the Code of Business Conduct and Ethics due to the importance of proper conduct within the healthcare community. In 2022, 100% of employees participated in training. In 2023, we opted to have all new employees undergo training, and prioritize integration efforts with existing employees who participated in training in 2022.

Practicing Ethical Responsibility in the Healthcare Community

We expect all Catalyst employees to uphold the highest ethical standards of business conduct when working with patients, physicians, customers, healthcare providers, and any additional stakeholders with whom they interact while performing their jobs. Our commitment to ethical responsibility remains consistent and of top priority as our business grows and we engage with additional products and an expanded patient base. Our Code of Business Conduct and Ethics outlines our high standards for professional conduct as well as representation of clinical trial data, including avoiding potential misrepresentations of facts.

We provide training for our field-based, customer facing employees who interact with health care professionals to comply with the PhRMA Code on Interactions with Health Care Professionals (the "Code"). The Code reinforces how interactions with healthcare professionals are professional exchanges designed to benefit patients and enhance the practice of medicine.

In the event any potential violation is reported, an investigation would be launched to determine if any violations occurred. In the case of violations, Catalyst would institute corrective and/or disciplinary actions.

Bribery & Corruption

Our Code of Business Conduct and Ethics states that all personnel employed by Catalyst must adhere to the U.S. Foreign Corrupt Practices Act and must not accept or offer any gifts to government personnel. Employees are given training upon hire and bi-annually devoted to anti-corruption policies and procedures as well as legal actions for this behavior and anti-trust and monopoly practices ensuring compliance with these guidelines.

As our business expands beyond low-risk countries (U.S., Canada, EU, and Japan) to potential partners in higher-risk countries in Latin America and Asia, we have implemented a third-party due diligence process for potential trading partners in countries with higher risks of corruption.

In 2023, Catalyst had no monetary losses as a result of legal proceedings or investigations associated with bribery and corruption allegations. Additionally, Catalyst has not been subjected to any investigations or proceedings related to concerns that it engaged in any behaviors that promote anti-competitive, anti-trust, and monopolistic practices.

Whistleblower Protections

At Catalyst, we encourage our personnel to hold each other accountable by reporting critical concerns or violations of our Code of Business Conduct and Ethics. Any Catalyst personnel who reasonably believe that there has been a material violation of our Code is required to report the potential violation to their supervisor, Chief Compliance Officer, Chief Financial Officer, Chief Executive Officer, and/or the Lead Director of the Board of Directors. Additionally, whistleblower or external reports of ethical concerns can be made electronically via our EthicsPoint webpage including anonymous reporting options. Catalyst ensures that there will be no retaliatory action taken against employees, or others, for reporting violations of the Code in good faith.

All reports involving a director or executive officer will promptly be investigated by the Audit Committee, with all other reports being assigned to our Chief Legal and Compliance Officer. Additionally, all violations of the Code of Conduct are reported to the CEO and/or the Board of Directors. If the investigation leads to a conclusion that a material violation of the Code of Conduct has occurred, the Company will take appropriate corrective action, which may include termination of one's position with Catalyst.

Ethical Marketing

Catalyst is committed to fair and ethical conduct and complies with all laws and regulations. Our Code of Business Conduct and Ethics includes high standards that guide interactions with physicians and patients, professional conduct, representation of clinical trial data, and steps to take to avoid any potential misrepresentations of facts. This includes processes to avoid misconstruing the suitability of products and making false claims about the efficacy or safety of drugs.

All Medical Affairs and Commercial employees are required to participate in Code training upon joining the Company – which covers responsible marketing, advertising, and sales practices, including labeling and promotion – in addition to routine follow-up training. In 2023, we added several Commercial employees to our team. With this addition, we ensured all Commercial employees received comprehensive onboarding to enable a consistent understanding of our high-quality and ethical marketing practices and standards. New products are integrated into ethical marketing procedures to ensure that employees continue to interact with medical staff ethically. This is a recurring part of compliance training annual refreshers for our Commercial team, with a focus on helping physicians understand the optimal patient choice for our products.

SOCIAL

Growing with a Diversified Portfolio

At Catalyst, our mission has always been to improve the lives of those suffering from rare and difficult-to-treat diseases. Over the past year, we capitalized on opportunities to acquire and license clinically differentiated and adequately de-risked products to further address critical unmet medical needs. We also broadened our global reach, expanding our commercial footprint through strategic partnerships and exploring commercial add-on assets both in the U.S. and abroad. As we progress along our exciting growth trajectory, we are committed to upholding Catalyst's rigorous standards across our product portfolio and delivering on our promise of providing patients with the medications that they need and can rely on through thoughtful product acquisition practices, robust quality standards, and comprehensive safety procedures.

FIRDAPSE® (amifampridine) Tablets 10 mg

aGamree™ (vamorolone) oral suspension 40mg/mL

Fycompa™ (perampanel) TABLETS 2 • 4 • 6 • 8 • 10 • 12 mg ORAL SUSPENSION 0.5 mg/mL

2023 marked a critical year for Catalyst as we expanded and diversified our product portfolio, with a particular focus on targeting rare (orphan) central nervous system ("CNS") and other adjacent CNS diseases. We have advanced our commercial portfolio expansion strategy through comprehensive search and evaluation efforts centralized around two key pillars:

First, focusing on broadening and diversifying our rare and difficult-to-treat product portfolio with sufficiently de-risked innovative therapies that address critical unmet medical needs; and

Second, expanding the geographic footprint of our existing products, with the current focus on the Asia Pacific and Latin American regions.

We are dedicated to delivering innovative medicines to make a meaningful difference for patients living with rare and other difficult-to-treat diseases, and we will continue to invest in unique and clinically differentiated opportunities in order to serve more patients.

Catalyst's product portfolio currently consists of three products:

FIRDAPSE® (amifampridine) Tablets 10 mg

[Neuromuscular] FIRDAPSE® for rare neuromuscular disease

Catalyst's flagship product, the only U.S. approved and available treatment for Lambert Eaton Myasthenic Syndrome ("LEMS") rare neuromuscular disease, for adults and for pediatric patients 6 years of age and older. LEMS is a rare autoimmune condition that interferes with the ability of nerve cells to send signals to muscle cells. FIRDAPSE® is clinically proven to help patients maintain muscle strength and mobility.

aGamree™ (vamorolone) oral suspension 40mg/mL

[Neuromuscular] AGAMREE® for rare muscular dystrophy disease

AGAMREE® is a novel corticosteroid for the treatment of Duchenne muscular dystrophy ("DMD") in patients 2 years of age and older. Its unique mode of action is based on differential effects on glucocorticoid and mineralocorticoid receptors and modifying further downstream activity. We expect that AGAMREE® will address an important unmet need for DMD patients and caregivers in the United States.

Fycompa™ (perampanel) TABLETS 2·4·6·8·10·12 mg ORAL SUSPENSION 0.5 mg/mL

[Epilepsy] FYCOMPA® for specific categories of epileptic seizures

FYCOMPA® is used to treat certain types of focal onset seizures in adults and children four years of age and older. It is also used in combination with other medications to treat certain types of primary generalized tonic-clonic seizures in adults and children 12 years of age or older. It works by decreasing abnormal electrical activity in the brain, and it was the first, and still the only, drug of its class to be approved for epilepsy.

Research, Development, and Strategic Collaborations

2012

Catalyst entered a strategic collaboration for the North American rights of FIRDAPSE® with BioMarin Pharmaceutical, Inc.

2018

NOVEMBER 2018

FDA approves FIRDAPSE® (amifampridine) for the treatment of LEMS, the first evidenced-based medicine approved to treat LEMS

2019

JANUARY 2019

Launched FIRDAPSE®

Catalyst launched its FDA approved FIRDAPSE® (amifampridine) for the treatment of LEMS in the United States

2020

JANUARY 2020

BioMarin transferred substantially all of its rights under the FIRDAPSE® License Agreement to SERB SA

JULY 31, 2020

New Drug Submission filing for FIRDAPSE® was approved by the Health Canada

AUGUST 2020

Catalyst licensed the Canadian rights for FIRDAPSE® for the treatment of LEMS to KYE Pharmaceuticals (KYE)

2021

2022

SEPTEMBER 2022

Approval of supplemental NDA ("sNDA") for FIRDAPSE® for the treatment of LEMS in patients age 6 and older

2023

JANUARY, 2023

Acquired the U.S. rights FYCOMPA®

Catalyst acquired the U.S. rights to FYCOMPA® from Eisai and a Supply Agreement for Eisai to manufacture FYCOMPA® for Catalyst for at least the next seven years

JULY, 2023

Obtained an exclusive North America license, manufacturing and supply agreement for AGAMREE®

OCTOBER 2023

The FDA accepted for review Catalyst's supplemental New Drug Application ("sNDA") to increase the indicated maximum daily dosage of FIRDAPSE® (amifampridine) Tablets 10 mg from 80mg to 100mg

The FDA approved AGAMREE® for use in patients with DMD ages 2 and older

DECEMBER 18, 2023

Our sub-licensee for FIRDAPSE® in Japan, DyDo Pharma, Inc., filed a Japan NDA with the Pharmaceuticals and Medical Devices Agency (PMDA) for product commercialization in Japan. Upon acceptance of the Japan NDA by the PMDA, our license for FIRDAPSE® automatically expanded to include other key markets in Asia and Latin America

2024

MARCH 2024

Commenced the commercial launch of AGAMREE®, an innovative alternative steroid treatment for DMD in the United States

MAY 30, 2024

The Prescription Drug User Fee Act ("PDUFA") action date assigned by the FDA for increasing the maximum daily dosage of FIRDAPSE® to 100mg. This marks yet another milestone in the advancement of our initiative to address an important need of LEMS patients and their physicians who desire an increased daily dosage.

Expanding our Geographic Reach

As part of our growth strategy, we are focused on expanding the geographical footprint of existing Catalyst products. Under our FIRDAPSE® license agreement with SERB SA., our license for FIRDAPSE® extends to Japan and other key markets in Asia and Latin America. In addition to the rights to market in North America, our AGAMREE® license agreement provides us with the right of first negotiation for AGAMREE® in Europe and Japan in the future should our licensor determine it is outlicensing those rights. Additionally, we will hold the North American rights to any future approved indications for AGAMREE®. We believe broadening the geographical reach of our products is key to ensuring access and reaching more patients in need.

Product Innovation

The collective mission of Catalyst's development program is to advance the treatment options for patients living with rare and other difficult-to-treat diseases. As part of our ongoing growth and portfolio expansion strategy, we are focused on lifecycle management to maximize the impact of Catalyst products through new applications for existing diseases. Catalyst has conducted extensive clinical development for FIRDAPSE® and is well-positioned to apply the same thoughtful and comprehensive approach to unlock additional value across its product portfolio.

Over the course of its involvement with the product, Catalyst has dedicated resources to explore and pursue research and development activities for the potential use of FIRDAPSE® in treating various rare diseases. Despite the outcomes of these studies, our commitment to funding further clinical trials remains steadfast as we continue to explore the full potential of our innovative products. These areas of exploration include:

LEMS
Lambert-Eaton Myasthenic Syndrome

CMS
Congenital Myasthenic Syndrome

MUSK-MG
Myasthenia Gravis

SMA
Spinal Muscular Atrophy



Additionally, in December 2023 and January 2024, the U.S. Patent and Trademark Office ("USPTO") issued two new patents which cover methods of treating LEMS with FIRDAPSE® under fasting and fed conditions of dosing. We continue to pursue additional patent applications for FIRDAPSE® in an effort to further protect our drug product.

Significant strides have been made in extending FIRDAPSE's® label in the U.S. to include a 100 milligram maximum daily dosage. This focus has been driven by feedback from the LEMS patient and provider community expressing a need for a higher daily dose and underscores our commitment to integrating patient input into our decision-making. Catalyst announced on May 30, 2024 that the label expansion to the higher daily dose was approved to enable physicians greater flexibility to titrate patients to an optimal dose.

We look forward to building upon this important progress to expand the use of FIRDAPSE® and evaluate similar opportunities for our new products, FYCOMPA® and AGAMREE®. Through our efforts, we believe we are truly making a difference in the lives of our patients and those suffering from rare and other difficult-to-treat diseases.

Steps of Drug Development

DISCOVERIES
Researching possible new methods to treat disease
Developing or discovering new molecules, technology, or new uses for existing medicines

NONCLINICAL TESTING
Determines safety and shows effectiveness in the target disease
Animal testing obtains safety data about effects on multiple internal organs and proves potential efficacy of the compound

PHASE 1
Tests the safety of the medicine
The safety is carefully tested in healthy volunteers, people with kidney or liver problems, and sometimes in people with the rare disease. Even more studies seek information about how and when the medicine reaches specific body tissues

PHASE 2
Studies in small groups of people with the disease to establish dosing and to identify potential side effects
Tests if the medicine works in people with the condition and determines potential side effects and best dose

PHASE 3
Compares participants receiving the new medicine to those in the control group
The control group may receive a placebo (an inactive medicine) or the current standard treatment

Clinical Trials
Many research studies are done in people to evaluate the medicine's efficacy and safety

Approval

PHASE 4
Post-marketing surveillance and pharmacovigilance
Monitors the product for long-term safety and efficacy

Industry Engagement and Advocacy

Catalyst has been a long standing member of various industry organizations, demonstrating our commitment to rare disease communities through advocacy, medical research, pharmaceutical industry guidance, patient advocacy, and other related activities. Through our involvement in these organizations, we stay abreast of industry trends and continue on our journey to develop innovative products for rare and difficult-to-treat diseases. We actively engage with the following organizations:

Disease and Medical Research

BIOTECHNOLOGY INNOVATION ORGANIZATION

The **Biotechnology Innovation Organization** is the world's largest advocacy organization representing member companies, state biotechnology groups, academic and research institutions, and related organizations across the world.

BIOFLORIDA

BioFlorida represents Florida's life sciences industry and 8,600 establishments and research organizations in BioPharma, MedTech, Digital Health, and Health Systems. BioFlorida's member driven initiatives provide a strong business climate for the advancement of innovative products and technology that improve lives and promote economic benefits to the state.

Industry Standards

PPSWG

The Pharmaceutical Product Stewardship Work Group ("PPSWG"), an organization that is committed to providing infrastructure, guidance, and subject matter expertise to support member compliance and improve awareness of existing pharmaceutical disposal options at the consumer level. Through participating in the Work Group, our membership in this organization, we stay informed about the latest developments in best practices, as well as legislative and regulatory updates in the pharmaceutical industry.



Patient Advocacy

Catalyst regularly engages with over 20 patient advocacy organizations, including those supporting patients with LEMS, epilepsy, muscular dystrophy, and more. These organizations connect with patients, families, caregivers, advocates, and clinical partners through advocacy, education, research, and various patient services. Some of the key patient advocacy organizations we collaborate with include:

Click logo links to navigate to the organization website

LEMS

Epilepsy

Muscular Dystrophy

With a proven track record in acquiring and commercializing novel medicines, we continue to seek partnerships and opportunities to diversify our presence in neurological and rare diseases, while simultaneously increasing our commercial footprint to achieve greater impact and further enhance patient access and outcomes. As we build on the momentum of 2023, we are well-positioned to continue delivering strong and sustained growth while expanding our reach, fulfilling our commitment to making a meaningful difference for patients living with rare and other difficult-to-treat diseases.

Product Quality & Patient Safety

Catalyst is committed to improving the lives of those who suffer from rare and other difficult-to-treat diseases. Through robust quality standards, comprehensive safety procedures, and active engagement with our patient community, we are able to follow through on our promise to provide patients with safe, accessible, and affordable medication.

Drug Safety

Testing and Quality Standards

We recognize the vital role our products play in improving our patients' lives. Therefore, we work rigorously to ensure we produce best-in-class, high quality products at all time. Our dedication is rooted in our belief that medication should be safe and effective.

Every Catalyst product undergoes rigorous testing to ensure it meets stringent criteria for purity, potency, and quality before being approved for use. Given that our new products obtained in 2023 are primarily through licensing partnerships, we further integrated our processes, as detailed in the following section, into our existing manufacturing.

As part of our commitment to ensuring patients have access to the highest quality medicines, we follow the United States Pharmacopeial ("USP") convention guidelines to establish quality standards for our products, and we mandate that our third-party suppliers and contract manufacturers maintain compliance with all relevant current Good Manufacturing Practices ("cGMP") in their management and manufacture of Catalyst products. Additionally, we support and facilitate appropriate oversight of manufacturing, testing, and quality processes by regulatory agencies, which we view as an opportunity to receive unbiased validation and feedback on our practices. Inspections of our vendors' manufacturing facilities conducted by the FDA or other authorities ensure Catalyst's compliance and assure that the facilities, methods, and controls used in manufacturing Catalyst products preserve and maintain the drug's identity, strength, quality, and purity.

As part of our adherence to the cGMP, Catalyst invests significant time, money and effort with our suppliers and contract manufacturers in areas of development, testing, production, record-keeping, and quality control. We conduct onboarding safety training sessions with new vendors to ensure they understand and adhere to health and safety reporting requirements outlined in their contracts. Additionally, we conduct annual refresher training sessions with our existing vendors to maintain alignment on ongoing health and safety monitoring and reporting protocols. Our close collaborations with manufacturing vendors ensure our ability to consistently deliver safe and effective products to our patients.

In the case of a disruption that may affect product quality or supply, our contingency plans and mitigation control systems help ensure Catalyst can continue to provide safe products to patients. Catalyst addresses potential issues at their origin by distributing finished goods across multiple locations, thereby minimizing the risk of a substantial quantity of stock being compromised. We also maintain an appropriate level of safety stock, based on historic usage, to help ensure patients can continue to receive their necessary life-saving drugs without disruption.

AS A RESULT OF OUR CONTINUOUS EFFORTS TO PRODUCE BEST-IN-CLASS PRODUCTS, WE CAN CONFIDENTLY AFFIRM THAT CATALYST PRODUCTS WERE NOT SUBJECT TO ANY PRODUCT OR UNIT RECALLS IN 2023, INCLUDING RECALLS IN NON-U.S. MARKETS AND THOSE NOT SUBJECT TO FDA REPORTING.

In rare instances where a product is returned to a specialty pharmacy by the patient or others, Catalyst will cover the cost of the product destruction. These initiatives and processes reflect our commitment to minimizing the risk of diversion, safeguarding water from contamination due to improper disposal, and preventing improper medication use.

Patient Safety

From the initiation of clinical trials to the commercialization of our products, patient safety remains a top priority for Catalyst. We are dedicated to providing patients with the resources and knowledge they need to effectively manage and enhance their well-being, as we believe patients who are actively engaged in their healthcare make informed decisions that not only improve their own health outcomes, but also positively impact the health and lives of others. That is why we ensure mechanisms are in place for Catalyst to integrate patients' input into our decision-making processes.

Our 2023 Clinical Trial Activities

Our therapeutic focus has expanded from LEMS to cover DMD and epileptic seizures. Historically, Catalyst's primary clinical trials were associated with LEMS, and we have partnered with contract research organizations ("CRO") in the U.S. for tasks within the trial management process, such as identifying sites, setting up a trial master file, and performing statistical analysis, while Catalyst oversees all other aspects of our studies. With our expanded portfolio, we tailor processes and procedures for commercializing our new products while maintaining the same level of rigorous standards.

In addition to acquiring the U.S. rights to FYCOMPA® from Eisai Co., Ltd ("Eisai"), we have also inherited five Investigator Initiated Studies related to FYCOMPA® within the U.S., all of which are nearing completion or have completed. In 2023, we also closed out FIRDAPSE® studies for both our Myasthenia Gravis (MuSK-MG) clinical trial and our previously operated expanded access program for non-LEMS patients though compassionate use access continues. Additionally, to support the approval of AGAMREE®, Catalyst is initiating a long-term registry study focusing on the long-term safety and quality of life in males with DMD that are treated with AGAMREE® in the U.S. and is also assuming control from Santhera of an expanded access program for vamorolone in Canada.

Selecting Clinical Trial Participants

The process of obtaining informed consent from participants in clinical trials is specific to the study and site in focus. We provide for each study a template for Informed Consent Forms ("ICF") in addition to the detailed protocol. Note, each ICF is developed in accordance with each site's requirements and their Institutional Review Board ("IRB"). Further, we ensure that the minimal elements of informed consent are contained in each site's version, and we complete site audits to confirm documentation, verify that the necessary steps are being followed, and ensure that the ICFs at each site are up to date with current study information.

Safety of Clinical Trials

Catalyst ensures clinical trial safety through meticulous controlled processes, policies, standard operating procedures, and an overarching document management system. Each clinical trial and commercial product undergoes thorough reviews from medical and safety perspectives utilizing highly targeted standard operating procedures. Catalyst also maintains a pharmacovigilance team that follows similar standardized processes, policies, and standard operating procedures when conducting safety surveillance, investigations, and reporting across all of our operations, including medical surveillance post-clinical trials. Safety procedures include an annually updated safety report submitted to regulatory authorities, including the FDA, and a thorough assessment of any Serious Adverse Events that are reported from clinical trial sites or patients.

Catalyst leverages the mechanisms described in our Standard Operating Procedures ("SOPs") to ensure that all vendors involved in clinical trial activities meet the requirements outlined in relevant national and international standards, such as FDA regulations pertaining to Good Clinical Practices ("GCP"), the ICH guidelines, all trial subject protections from the Helsinki Declaration, as well as other comparable resources, references, and requirements. We also utilize SOPs to oversee vendor qualification, related requirements tracking, overall quality management plan, and Good x Practice (GxP) audit planning and execution, specifically including manufacturing and clinical trial quality audits. We also ensure all clinical trial staff is trained appropriately to uphold the standards outlined in our SOPs. Together, our SOPs establish a set of quality and safety benchmarks and provide a framework for monitoring and initiating corrective actions when necessary.

Compassionate Use Programs

Catalyst continues to make FIRDAPSE® available to a limited number of patients diagnosed with Congenital Myasthenic Syndromes or Downbeat Nystagmus ("DN") through investigator-sponsored compassionate use programs. We also offer patients access to amifampridine through compassionate use supplies, which serve as a potential avenue for individuals with serious or immediately life-threatening diseases to access investigational medical products or an investigational use for an approved product for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.

Formal requests for compassionate use access to Catalyst products in development may only be made by licensed prescribers with the authority to administer and oversee treatment of patient(s) on whose behalf the request is made. All requests must include documentation and are reviewed by the Catalyst Chief Medical Officer based on a two-part analysis that addresses if the product is appropriate for compassionate use access and if the patient is an appropriate recipient for compassionate use access. Catalyst believes granting this option to patients aligns with our goal of promoting expanded access to our medicines for patients seeking innovative therapeutic options.

For additional information, please refer to our Compassionate Use Policy available on our website.

Patient Safety for Market Stage Products

Catalyst believes that safeguarding patient safety post-commercialization of our products is just as crucial as ensuring safety during clinical trials. This includes adhering to regulations, monitoring product quality and efficacy, and providing patients with the support they need.

For continuous monitoring of our market stage products, Catalyst maintains a dedicated pharmacovigilance ("PV") department specialized in post marketing surveillance and pharmacovigilance. The PV department is responsible for overseeing various programs aimed at monitoring the long-term safety and efficacy of our products.

As part of the post-approval process for FIRDAPSE®, the FDA required us to conduct a clinical trial to evaluate the effect of hepatic impairment on the exposure of amifampridine after oral administration of FIRDAPSE® relative to that in subjects with normal hepatic function. This study was completed and submitted to the FDA. Further, the FDA also required us to perform a second carcinogenicity study of amifampridine phosphate in mice, which has been completed and the FDA has advised us is acceptable. Finally, in connection with the recent approval of our sNDA for FIRDAPSE® for the treatment of children ages six through seventeen with LEMS, we are now completing a pediatric safety study of juvenile toxicity in a rodent, as required by the FDA. As part of our monitoring activities, Catalyst also established a pregnancy surveillance program to collect and analyze information for a minimum of ten years on pregnancy complications and birth outcomes related to FIRDAPSE®.

In addition to FIRDAPSE®, we are conducting post-approval monitoring studies for AGAMREE®, which include two carcinogenicity studies similar to those of FIRDAPSE® and a trial to evaluate the CYP3A4 induction potential of vamorolone in a dedicated clinical drug-drug interaction study, addressing the serious risk of altered pharmacokinetics of CYP3A4 substrates when used with vamorolone.



Patient Advocacy

We are constantly inspired by the resilience and strength of individuals fighting the unique challenges of living with rare and other difficult-to-treat diseases, and the perspectives of those affected by these conditions are paramount to our work.

In addition to complying with FDA regulations and ensuring product safety, **supporting and advocating for patients** is another top priority of Catalyst, as underpinned by our patient-first culture. We believe that empowering our patients to manage their conditions adds another layer to ensure patients' safety and better health outcomes. Our approach involves collaborating with patient organizations, raising awareness for key patient issues, fostering connections among individuals and families affected by rare diseases, and developing initiatives tailored to the specific needs of each patient community.

"From our first interaction, Catalyst expressed the will to support patients, interact with advocacy groups, and continually look for ways to spread awareness for our under-publicized disease state."

Brad Levy, Co-founder Sophie's Journey (Epilepsy Patient Advocacy Group)

Over the past year, we tripled the size of our patient advocacy team to broaden our engagement with the LEMS patient community and forged new partnerships with advocacy groups focusing on epilepsy and DMD. For example, Catalyst's Neuromuscular Medical Science Liaisons ("MSLs") have intensified efforts over the past year to connect with traditional FIRDAPSE® prescribers and oncology providers, emphasizing the importance of testing patients for LEMS including those who may benefit from the treatment of FIRDAPSE®, particularly for SCLC patients.

Additionally, since AGAMREE®'s approval in October 2023, our Advocacy and MSL teams have been actively engaging with the DMD patient and provider community. Through our proactive and close collaborations with these touchpoints, we were able to integrate the patient community's voices and needs into our regular business engagement, including with providers. Learnings from these interactions further inform our patient-focused advocacy initiatives, which are tailored to each patient group.

Jett Foundation is among the many DMD patient organizations that we proactively engage with.

"Our partnerships with industry partners are crucial to ensuring the patient voice and experience is represented. We are grateful to industry partners like Catalyst who engage with us regularly and participate in our community events and programs. Together we are stronger than Duchenne."

Maura Carroll, Director of Development of the Jett Foundation

Moreover, we also dedicate resources to facilitate connections among individuals affected by rare and other difficult-to-treat diseases, allowing them to share their experiences and stories. This objective stems from our belief that fostering a sense of community among patients helps them connect and navigate their conditions through mutual support. For instance, on Rare Disease Day in February 2022, Catalyst launched a podcast called *LEMS Aware* to help raise awareness of the important need for new treatments for rare diseases that affect small patient populations. Produced by Catalyst and created to increase awareness of and connections in the LEMS community, the podcast invites LEMS patients, physicians, and influencers in the rare disease community to discuss topics unique to LEMS and the rare disease community as a whole. In 2023, we published two new episodes, and we continue to invest in and explore our approaches to facilitate conversation and knowledge sharing, as additional episodes are scheduled for 2024. **To access the LEMS Aware podcast, please visit the LEMS Aware website.**

On February 28, 2023, Catalyst rang the Nasdaq Closing Bell in recognition of International Rare Disease Day to help shed light on the important unmet need for rare diseases in partnership with leading advocacy groups.

We are immensely proud to witness the growing awareness of the LEMS community, and our commitment to standing alongside our patient community remains unwavering. On March 30th, 2024, Catalyst announced its endorsement of the inaugural LEMS Awareness Day created by the LEMS Family Association. This landmark event marks a meaningful milestone for the LEMS community. The observed date chosen carries profound historical significance, coinciding with the publication of Dr. Edward Lambert and Dr. Lee Eaton's pioneering research on LEMS, which has greatly advanced to the comprehension and treatment of this rare neuromuscular disorder.

"In the realm of rare diseases, awareness is the key that unlocks paths to diagnosis and treatment. By shedding light on LEMS, we pave the way for better support, understanding, and care for those who need it most," stated **Richard J. Daly, CEO of Catalyst**. "At Catalyst, we are proud to stand alongside the LEMS Family Association in honoring this pivotal event. Together, we forge pathways of support and understanding for those affected by rare diseases, illuminating a brighter future for all."

Our extensive involvement with the LEMS community has demonstrated the effectiveness of our approach, resulting in an increased awareness of the disease among the general public. Looking forward, we are excited about leveraging our experience to deepen our connections with the patient communities and advocacy groups focused on epilepsy and DMD to drive meaningful advancements in their treatments and to assist them in navigating their conditions.

Supply Chain Management

As a US-based company, Catalyst exclusively operates within the North American market. We hold distribution rights to FIRDAPSE® in the United States and Mexico, while sublicensing the rights for Canada and Japan to other entities. In 2023, we acquired the U.S. rights to FYCOMPA® and the rights to commercialize AGAMREE® in North America as part of our efforts to diversify our product portfolio and increase our global footprint.

Catalyst operates as a virtual drug manufacturer licensed in Florida and does not own or operate any manufacturing facilities. Instead, we partner with contract manufacturers and packagers located in the U.S., Japan, and Europe. In 2023, we added four new suppliers for FYCOMPA® and three for AGAMREE®, all of which are situated in the U.S., Europe, or Japan. These suppliers were either previously associated with our licensing partners or, in some instances, the licensing partners themselves.

Catalyst takes a tailored approach to managing our supply chain to meet the unique demands of each of our products:

FIRDAPSE®

- Catalyst contracts the manufacturing of the active pharmaceutical ingredient ("API") contained in FIRDAPSE® and the finished goods through third-party manufacturers.

FYCOMPA®

- Eisai manufactures and supplies Catalyst with both API and finished FYCOMPA® tablets. The oral solution formulation of FYCOMPA®, as well as packaging of the product, is contracted to third-party manufacturers and there is an additional contracted API supplier.
- As a Schedule III drug[5], third-parties involved in the manufacturing, distributing, and dispensing of FYCOMPA® are required to maintain necessary Drug Enforcement Administration ("DEA") registrations and state licenses and comply with the regulatory requirements.

AGAMREE®

- Under our License and Collaboration Agreement with Santhera, we have agreed to purchase supplies of AGAMREE® from Santhera until January 1, 2026, after which we have the right to contract with third-party manufacturers for the manufacture and supply of AGAMREE®. Currently, Catalyst receives AGAMREE® finished goods (including API and packaging services) through Santhera and its vendors.

5. Drug Enforcement Administration Controlled Substance Code 2261

Catalyst implements various mechanisms, such as annual supplier assessments and training, to uphold our stringent quality and safety standards across the supply chain. This past year, we invested time and resources to ensure newly onboarded suppliers would experience a smooth transition to our standard processes. Additionally, through our membership with various pharmaceutical supply chain standard setting organizations, we help ensure Catalyst remains abreast of best practices for maintaining product quality and traceability. Through these methods, we have built a culture of trust and collaboration with our suppliers which have consistently been able to deliver products that meet our standards. Therefore, we plan to maintain our contract manufacturing model while continually monitoring the necessity for in-house manufacturing capabilities.

Assessing Suppliers

Catalyst prioritizes relationships with suppliers that share our values regarding product quality, safety, and commitment to best practices. When selecting suppliers, we conduct comprehensive assessments to ensure potential suppliers are aligned with our standards. This includes all selected contractors undergoing FDA inspections to ensure they are in substantial compliance with federal regulations and manufacturers regularly demonstrating compliance with the FDA's current Good Manufacturing Practices regulations and our internal policies. All current Catalyst suppliers, including those that were added this year, have demonstrated compliance with our quality assessment requirements.

When evaluating our suppliers, we also ensure that our contract manufacturers adhere with all applicable environmental laws and regulations that affect the manufacturing process. Through regular monitoring, our manufacturers did not record any violations or significant direct exposure to environmental issues in 2023. As we further engage with manufacturers on environmental issues through our corporate responsibility program, we prioritize key aspects relevant to our business, such as waste management, packaging, and emissions across our value chain.

Supplier Training and Upholding Standards

To ensure our suppliers are equipped with the necessary resources and knowledge to maintain a safe workplace and produce quality products, Catalyst provides suppliers with various types of training. We conduct comprehensive onboarding sessions for all new suppliers to ensure they understand and comply with Catalyst's safety standards. Additionally, we conduct annual refresher training sessions for our suppliers to update and/or reinforce the latest safety procedures.

At Catalyst, all supply chain partners involved in post-product release activities are mandated to undergo specialized training. We provide adverse event and product complaint report training to staff at our patient services vendor, distributor/3PL provider, and primary specialty pharmacy vendors handling released products. Moreover, upon the initiation of a clinical trial, all investigators and staff receive training on the protocols for reporting adverse events and product complaints.

While Catalyst does not operate any manufacturing facilities, we remain responsible for the packaging of our products in preparation for distribution. We adhere to FDA regulations to ensure that no recycled materials are used in packaging that comes into direct contact with our products. Catalyst is responsible for all aspects of the labeling of our products – including those performed by third-party vendors. As a result, we ensure that all of the public information about our products, including promotional material and advertising, remains accurate, compliant, and totally aligned with each product's FDA-approved labeling and based on available well-controlled scientific data.

To maintain Catalyst's standards across our supply chain, we execute supplier audit programs to regularly monitor supplier practices. Approximately 63% of our Tier 1 supplier facilities participate in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program, which addresses pharmaceutical and medical device supply chain security in relation to public health concerns and patient safety. By conducting both third-party and internal audits, we maintain confidence and visibility in our suppliers' capacity to adhere to our standards, particularly the current Good Manufacturing Practices, ensuring the production of safe and effective products.

Counterfeit Drugs

Catalyst recognizes the significant threat counterfeit drugs pose to public health and our Company's reputation. To mitigate this risk and safeguard our patients, we strictly adhere to all laws and regulations governing the serialization, traceability, and counterfeit prevention of pharmaceutical products. Moreover, for two of our products, FIRDAPSE® and AGAMREE®, we employ a stringent limited distribution system that provides visibility into the product distribution cycle throughout the value chain, even after initial distribution. For the other products, in addition to our standard measures, our licensor who is responsible for the world outside of the United States, maintains a worldwide monitoring program for counterfeit products. These measures reaffirm our commitment to integrity and upholding the highest ethical standards.

Catalyst is an active member of GS1, an organization that establishes standards for unique product identifiers. These standards play a crucial role in enabling international track and trace capabilities for serialized prescription drugs. By adhering to GS1 product serialization standards, we can accurately identify the source of serialized pharmaceutical products, effectively combating counterfeiting and diversion. Through our membership with this organization, Catalyst remains at the forefront of industry developments and adopts best practices to mitigate the risks associated with counterfeit drugs.

All Catalyst products prepared for the U.S. market are individual container serialized to allow for tracking throughout the supply chain. Leveraging our TraceLink system, Catalyst oversees the serialization of our products down to the individual package level in which each package unit, along with aggregate package units like cartons, cases, and pallets, is equipped with a barcode containing its unique serial number. Through our mature distribution network in the U.S. and our product serialization system, Catalyst creates a pedigree history, which can be used to effectively track and identify recipients of our manufactured and distributed products.

As a result of our methods and initiatives to prevent counterfeit drugs, Catalyst experienced no incidents related to counterfeit drugs in 2023. With that said, in the rare event of suspect product reports, our internal policy precisely delineates the steps that Catalyst employees and management should follow to inform patients, business partners, and the FDA if a product is determined to be counterfeit or illegitimate. Should Catalyst need to issue a recall, we would disclose this occurrence per our standard disclosure requirements up to and including initiating a recall. This process is outlined in our Standard Operating Procedure, which details how to determine when to initiate a recall and all subsequent activities until the recall has been terminated.

Human Rights

At Catalyst, safeguarding human rights is ingrained in our ethos, extending from our operations to our entire supply chain. Catalyst does not tolerate child labor, forced labor, or other breaches of human rights of any kind. With continuous efforts to monitor and enhance our mechanisms and policies, we are vigilant in preventing human rights incidents and ensuring immediate reporting and resolution of any incidents. Our commitment to ensuring a safe working environment has yielded positive results for another year, with no instances of human rights violations identified or reported by Catalyst or our suppliers in 2023.

Catalyst PATHWAYS®

Catalyst supports the distribution of FIRDAPSE® and AGAMREE® in the United States through Catalyst Pathways®, our personalized treatment support program which supports our patients through challenging dosing and titration regimens required to reach an effective therapeutic dose. Catalyst Pathways® also works with a small group of exclusive specialty pharmacies that dispense FIRDAPSE® and AGAMREE®. The low volume of distribution and limited patient base – most of whom Catalyst is in contact with through the Catalyst Pathways® program – alongside our recommendation that purchases only be made from recognized and approved vendors within that small supply chain significantly decreases the risk of counterfeit products. Where applicable, we also leverage elements from the Catalyst Pathways® program for FYCOMPA®. Read more about Catalyst Pathways® in the Access to Healthcare section of this report.

Access to Healthcare

We remain steadfast in our commitment to leave no patient behind, regardless of their ability to pay.

Access to Medicines

Our unwavering commitment to the patient communities we serve is demonstrated through our continuous efforts to enhance awareness of rare and other difficult-to-treat diseases, provide patients with personalized support systems, develop financial assistance programs to reduce out-of-pocket costs, and explore opportunities to expand access to our products around the world. To uphold our commitment, updates on initiatives and results associated with access to medicines are regularly communicated and reported to the Board. As we expand our drug portfolio, Catalyst remains focused on these efforts to ensure that each of our products, including FIRDAPSE®, FYCOMPA®, and AGAMREE®, are available and accessible to all patients who need them.

Catalyst Pathways®

Catalyst Pathways® is a free, personalized, and comprehensive assistance program created by Catalyst to offer patients and their caregivers intuitive and comprehensive one-on-one support throughout their treatment journey. Through this program, we ensure LEMS and Duchenne muscular dystrophy ("DMD") patients have access to Catalyst medicines regardless of their ability to pay.

The Catalyst Pathways® program provides a range of patient-focused services, including educational resources, insurance information, and assistance in identifying eligibility for financial assistance programs. Additionally, the program includes a delivery assurance program, in which Catalyst team members monitor, anticipate, and plan for potential drug delivery obstacles to ensure uninterrupted access to medication for patients.

In 2023, we expanded our Catalyst Pathways® patient service program to include the distribution of AGAMREE®[6]. This addition ensures that our DMD patients have access to a dedicated, personalized support team that can answer questions and coordinate financial assistance programs for eligible patients. We believe our efforts to incorporate AGAMREE® into the Catalyst Pathways® program demonstrate our unwavering commitment to leave no patient behind, as we expand our product and patient base.

6. FYCOMPA® is not available through the Catalyst Pathways® program because of its retail distribution model.



Understanding that people living with rare neuromuscular and neurological disorders need more than just innovative therapies to manage their unique health challenges, every patient enrolled in Catalyst Pathways® is assigned a Patient Access Liaison ("PAL"), a personal guide to navigate the following offerings of the program:

Medication support and educational resources: Helpful and easy-to-understand disease and treatment information.

Navigating insurance and reimbursement requirements: Services designed to ease patients' treatment experience and worries about treatment costs.

Patient Community Outreach Opportunities: Programs to connect patients with others who are on the same journey.

CONNECT WITH OUR TEAM OF CARE COORDINATORS AND PATIENT ACCESS LIAISONS ("PALS") TO UNDERSTAND YOUR MEDICATION AND FIND THE RESOURCES AND HELP YOU NEED, PLEASE FOLLOW THE LINK TO CHOOSE YOUR PATHWAY.

"For the first time in my career, I can visibly see the results of my efforts. Being able to meet with a patient once diagnosed and stay with them along their personal journey has been more rewarding than any other job I have had or ever dreamed of having."

— Amy, Catalyst Patient Access Liaison

Catalyst Pathways® is also the gateway for the following assistance programs:

Third-Party Foundation Assistance: If a patient is having trouble paying their out-of-pocket costs, Catalyst Pathways® can direct them to nonprofit organizations that can help them pay for their medicine. Call Catalyst Pathways at 1-833-422-8259 for further information.

Free Bridge Medication: Through our Catalyst Pathways® program, we offer free medications for qualified LEMS and DMD patients while they are waiting for coverage determination or for patients whose access is threatened by the bureaucratic complications arising from a change of insurer.

Patient Assistance Program ("PAP"): Catalyst Pathways® provides longer-term free medication for FIRDAPSE® and AGAMREE® patients who are uninsured or functionally uninsured because they may be unable to obtain coverage from their payor despite having health insurance.

Through Catalyst Pathways®, we have also established a Patient Ambassador program of FIRDAPSE® to connect individual patients, which facilitates the discussion of their disease journeys and addresses disease-related questions. This initiative fosters a sense of community among patients, where they feel acknowledged and supported by one another. Building on the success of this program with FIRDAPSE®, we are extending it to establish similar programs for both FYCOMPA® and AGAMREE®.

"I've felt more supported than I have in the last 30 years of having LEMS. Catalyst is doing a great job bringing LEMS into focus, raising awareness. I am thrilled to have a company that's helping guide me and my community, bringing us together."
—Julianna, Living with LEMS

"The attention we've received thus far has been outstanding!"
—Mother of an DMD patient

We are proud of our efforts to connect with the patient community and increase access to and affordability of our products through the Catalyst Pathways® program. We believe our progress in this area reinforces our commitment to the patient community and serves as a testament to our willingness to go above and beyond to ensure our patients have access to the life-saving medications they need. As we continue on our path towards strategic portfolio expansion, we look forward to providing our patients with this level of care through the Catalyst Pathways® program and additional efforts that are described in the section to the right.

Additional Efforts to Optimize Coverage and Access

At Catalyst, we believe that all patients should have access to affordable medicine. Through our pricing strategies, we ensure Catalyst medication is appropriately priced and support systems are available to facilitate affordable access for all patients, especially those who otherwise cannot afford the medication. Moreover, we are dedicated to donating funds to qualified, independent charitable foundations that assist patients in financial need. Our commitment to equitable and consistent pricing is demonstrated by consistent price changes proportional to inflation rates year-over-year, subject to specific needs or issues associated with life cycle management of a particular product.

In addition to our Catalyst Pathways® program, we support our patients in the following ways:

Co-pay Assistance Program

We operate various financial assistance programs that are available to commercially-insured patients to reduce co-pays and deductibles to a nominal affordable amount.

FIRDAPSE®

- All LEMS patients with commercial coverage who are prescribed FIRDAPSE® have the opportunity to enroll in the FIRDAPSE® co-pay assistance program, which is designed to keep out-of-pocket costs to $10 or less per month (currently less than $2 per month).[7]

FYCOMPA®

- Catalyst supports FYCOMPA® patients through an Instant Savings Card Program. Through the program, eligible commercially insured patients could pay as little as $10 for their FYCOMPA® co-pay (with a maximum savings of $1,300 per year).[8]

AGAMREE®

- Similar to FIRDAPSE®, we support AGAMREE® with Catalyst co-payment assistance, reducing out-of-pocket costs to as low as $0/month for qualified patients with commercial insurance.

Compassionate Use

Through the FDA's Compassionate Use programs, patients in the United States who request our product from their physician prior to FDA approval have avenues to potentially gain access to our product at no charge. As outlined in our Compassionate Use Policy, Catalyst considers requests from physicians for compassionate use access for any of our products in the territories to which we have distribution rights. Catalyst currently makes FIRDAPSE® available to a limited number of patients diagnosed with Congenital Myasthenic Syndrome, MuSK positive myasthenia gravis, and Downbeat Nystagmus through investigator-sponsored compassionate use programs. In addition, we are working to integrate a Special Access Program for the distribution of AGAMREE® to certain DMD patients in Canada who participated in the AGAMREE® trials.

7. FIRDAPSE® co-pay assistance program is not available to patients enrolled in state of federal healthcare programs, including Medicare, Medicaid, VA, DoD, or TRICARE
8. The FYCOMPA® Instant Savings Card Program is not available to patients enrolled in state or federal healthcare programs, including Medicare, Medicaid, Department of Veterans Affairs (VA), Department of Defense (DoD), or TRICARE

Trial Vouchers and Sample Distribution for FYCOMPA®

To help broaden access for our patients and physicians, we offer starter doses of FYCOMPA® to healthcare providers to distribute to patients both through samples and through trial vouchers. We provide samples through a direct mail program to the healthcare providers and three voucher programs at varying levels which are each tailored to our patients' needs. This trial experience aims to simplify the decision-making process and broaden medication access for epilepsy patients.

Engaging the Duchenne Muscular Dystrophy Community

We actively engage with our patient community to better understand their needs. In 2023, immediately following the approval of AGAMREE®, Catalyst promptly responded to several invitations from individual advocacy groups, presented the product to their leadership and membership, and engaged in multiple meetings, including with members of the DMD community and key advocates, to gather feedback on pricing and medication access. We leverage this feedback to ensure our policies and pricing practices align with our commitment to responsible pricing while adequately addressing patient concerns.

Enhancing Awareness for LEMS Patients

We believe in the importance of educating and supporting patients and physicians on accessibility and treatment options to improve the lives of those living with LEMS. Catalyst offers an antibody test at no cost to health-care providers to definitively determine a patient's diagnosis with LEMS. Through educational and commercial activities, as well as collaboration with patient organizations, Catalyst is able to reach misdiagnosed and undiagnosed LEMS patients with an accurate diagnosis and help them with next steps to understand the treatment, and prescription process.

Many undiagnosed and misdiagnosed LEMS cases can be found within the population of patients with SCLC. In 2023, Catalyst published an abstract detailing the results from a study analyzing real-world data to determine the prevalence of LEMS diagnoses among patients with SCLC in the United States. In the same year, we reached 20,000 neurologists who are potential LEMS treaters and the 16,000 oncologists who might be treating a LEMS patient with SCLC. Through these targeted campaigns, we have successfully contributed to the identification of a higher number of diagnosed LEMS patients among SCLC patients.

Supporting Generic Alternatives

Catalyst also recognizes the societal value of developing generic alternatives to branded medications, subject to FDA exclusivities and existing patent protections. Catalyst is cooperative in supplying sample material to generic competitors, upon appropriate requests, to allow for the formulations of generic alternatives.

Our Employees

At Catalyst, we prioritize our employees by offering meaningful engagement and career development opportunities, alongside comprehensive health, safety, and well-being programs. As we expand our product portfolio and consequently, our workforce, we are taking care to ensure our legacy employee engagement opportunities and benefits are extended to the entirety of our workforce. We strive to provide employees with an inclusive, supportive, diverse, and growth-oriented workplace culture, which in turn, contributes to our ability to attract and retain top talent, an integral aspect of our Company's long-term growth and success.

Employee Recruitment, Development, & Retention

Our commitment to excellence drives our focus on attracting and retaining new talent. To support this, we have implemented several initiatives focused on employee recruitment, development, and retention, and we are actively expanding our workforce through tactics that seek to recruit talented individuals that are committed to fulfilling Catalyst's mission. Oversight of employee recruitment, development, and retention is managed by our Human Resources team. We have expanded our Human Resources team and increased the scope of their initiatives in order to ensure top-tier engagement with our growing workforce.

Workforce Overview

Our workforce is comprised of employees dedicated to three areas: commercial; research and development ("R&D"); and general and administrative ("G&A").

As part of our strategic efforts to expand our impact and reach, particularly with the additions of FYCOMPA® and AGAMREE®, we expanded our workforce significantly from 75 employees in 2022 to 167 employees as of February 2024. In addition, the composition of our workforce has shifted, with commercial employees accounting for 63% of our workforce, compared to 42% last year. This shift aims to support the growth of newly acquired products and our broader growth strategy. We believe the synergies in our existing neuromusucular franchise will allow Catalyst to scale our product portfolio and workforce efficiently.



Note: Based on data from 2023 10-K, calculated on February 28, 2024.

Talent Attraction & Retention

We have several programs to attract and retain top talent across the industry, as well as develop high-quality talent among our existing employees. In 2023, we expanded our Human Resources team and increased their scope of activities to support our growing workforce, ensuring that Catalyst not only recruits top-tier talent, but is also able to provide our expanded workforce with consistent support and resources. Our experienced team continues to adapt and scale our talent attraction strategy, with a particular emphasis on recruiting commercialization professionals as we grow.

While Catalyst relies on traditional recruiting methods such as job boards and recruiting from local universities, we also place a heavy reliance on internal methods that aim to develop our existing workforce and recruit indivduals from internal professional networks. We prioritize the development of our existing workforce to fill open roles, as these employees have extensive knowledge of our Company strategy and values. For example, our current CEO was a Catalyst Board member for many years before assuming the role of CEO. Additionally, many members of our Commercial team were brought to Catalyst from internal referrals, as these individuals often possess characteristics that align with our Company culture and beliefs. We believe this strategy fosters a collaborative and competitive company culture with high retention rates.

We demonstrate our appreciation for our employees through comprehensive compensation and benefits packages, coupled with robust training and development programs. We also award all new hires with stock options, providing employees with a tangible share in our future success. In 2023, we experienced a 9.1% employee turnover rate, a 4.2% decrease from 2022.

Employee Training and Development

Our operational approach to employee training includes providing all new hires with onboarding training covering important, position-specific, Company policies and procedures. We also provide specific onboarding training for commercial staff to ensure that they can effectively support the new products they support.

Throughout an employee's tenure at Catalyst, we provide refresher courses on Company policies, such as the Code of Ethics and Anti-harassment, ensuring all employees are well informed of our expectations and are fully equipped to perform their job responsibilities.

Catalyst encourages all employees to participate in our professional growth and development opportunities. Our tuition reimbursement program provides financial support for employees pursuing accredited degree or certification programs such as Continuing Medical Education ("CME"), Clinical Professional Education ("CPE"), Continuing Legal Education ("CLE"), and other job-specific certifications and training. We also occasionally offer an internship opportunity within our corporate office for a student from a local university. This program not only helps us connect with our community, but also supports the development of our talent pipeline.

Employee Engagement & Satisfaction

Catalyst prioritizes the development and implementation of meaningful employee engagement opportunities. We aim to achieve a high employee satisfaction rate by fostering a work environment where employees feel safe and valued, and have opportunities for career growth. To do so, we periodically seek feedback from our employees through our employee survey. This survey consists of engagement on critical workforce topics such as management practices, employee trust, Company policies, and Company communications.

All Catalyst employees participate in annual performance reviews to support their professional development and growth within our Company. As our workforce grows, we continue to offer optional mid-year reviews in which the majority of our employees elected to participate in 2023. Throughout these review periods, employees engage in collaborative conversations with managers in which they gain constructive feedback and determine next steps to continue on their path towards development at Catalyst.

Additionally, Catalyst hosts periodic department-wide and Company-wide meetings to foster an open discussion within teams and across our broader workforce. In these meetings, employees are encouraged to provide feedback, share recent wins, and discuss any challenges they may be facing in their positions. Through these conversations, we create a greater connection with our workforce and improve cross-functional communication between teams.

Employee Turnover Rates



Employee Benefits and Incentives

We offer employees a competitive benefits package including a 401K with a safe harbor match and a stock incentive plan for all eligible employees. We regularly review our incentive packages to ensure they align with our Company strategy and remain competitive in the current market. Our team is committed to ensuring that our employees are well-informed about their compensation packages and benefits.

Compensation packages for all employees include:

- Market competitive base salaries;
- Annual performance bonuses; and
- Stock option grants.

Our benefits programs include:

- Company-sponsored medical, dental, and vision health care coverage;
- Life and AD&D insurance;
- 401(k) plan with a matching employer contribution;
- Employee assistance program; and
- Tuition reimbursement program.

Catalyst has a number of flexible working approaches in which our employees are classified as in-office, hybrid, or remote based on their job duties and individual circumstances. Through this approach we provide our employees with flexibility to work in a way that balances work-life, job duties, and productivity, thus improving quality of work and overall satisfaction.

Employee Health & Safety

The health, safety, and well-being of our employees is critical to our business. In order to ensure a safe working environment for employees, Catalyst employees are required to understand and comply with corporate health and safety practices as outlined in our Code of Business Conduct and Ethics.

Given the nature of our operations, which includes corporate-based operations – both in office and field-based pharmaceutical support – hazardous activity has been assessed as a low risk for Catalyst. Catalyst reported zero work-related injuries and zero work-related illnesses in 2023.

Diversity, Equity, & Inclusion

Diversity, equity, and inclusion ("DE&I") is an important part of our mission to harness the potential of our workforce and is important to our long-term success. As part of our core values, Catalyst is committed to promoting an inclusive workplace where all employees feel valued, safe, and accepted.

We ensure that DE&I principles are integrated throughout our Company, from recruitment to professional advancement. This includes considering diversity when evaluating potential candidates for open positions and ensuring the hiring process is fair and equitable. We promote equal opportunities within our Company and prohibit discriminatory practices, prejudice, and harassment of any kind. To show our commitment, we also support staff-initaited DE&I activities, such as those celebrating Women's History Month.

Our commitment to DE&I is reflected in our employee demographics, as we seek to recruit employees with diverse background, experiences, and skills. Specifically, minority groups make up 39.6% of our overall workforce and 32.5% of our senior management. Additionally, 56% of our employees are female.

For comprehensive performance data on the gender, race, and ethnicity data of our workforce, reference the Performance Data Table in the Appendix of this report.

CATALYST DIVERSITY REPRESENTATION





Community Involvement

Catalyst is dedicated to supporting the communities in which we operate, as well as providing targeted assistance to our patient community. We actively engage with and contribute to our communities by donating resources and volunteering time to foster a more equitable society. In 2023, we focused on supporting community outreach to our new patient communities – epilepsy and Duchenne muscular dystrophy from our newly acquired products.

CATALYST'S VOLUNTEER DAY AT THE MIAMI ZOO

TO TAKE ADVANTAGE OF CATALYST'S VOLUNTEER DAY BENEFIT, IN WHICH ALL EMPLOYEES ARE PERMITTED UP TO ONE DAY PER YEAR TO VOLUNTEERS IN THEIR COMMUNITY OUTSIDE OF OTHER PAID TIME OFF BENEFITS, OUR ENTIRE HEADQUARTERS-BASED FINANCE TEAM TOOK A DAY TO VOLUNTEER AT THE MIAMI ZOO TO BOTH SUPPORT THE COMMUNITY AND BUILD THEIR OWN TEAM SPIRIT.

Supporting Communities in Access to Healthcare

Catalyst cares deeply about our patient community and is committed to fair and equal access to healthcare for all our patients. To ensure all patients have access to necessary treatment, we are committed to making our products available to all patients, irrespective of their identities, demographics, and financial abilities. Our ongoing goal is to prevent financial barriers from denying any patient access to their required medication.

To support our patient community, our Catalyst Pathways® program provides access to healthcare and patient services programs, as well as additional efforts to support our patients and their caregivers with financial and educational resources, and expanded access to FIRDAPSE® and AGAMREE®. Additionally, we have dedicated roles within our Company specifically focused on improving patient access to healthcare. These National Account Managers have extensive knowledge of payors and work to ensure patients have access to our medications through most commercial plans. We also have Medical Science Liaisons that support LEMS education and our ongoing clinical trial activities.

In 2023, we also established a dedicated resource team comprised of both patients and employees to address healthcare access issues in underserved communities. By addressing the needs of underserved communities, Catalyst works every day to try to ensure all members of our communities have access to healthcare and patient service programs. More information on these programs can be found in the Access to Healthcare section of this report.

As part of our community involvement strategy, we donate to qualified, independent charitable foundations that directly assist patients in the United States who face financial challenges. We also collaborate with healthcare professionals and rare disease advocacy groups to raise awareness and understanding of the rare and difficult-to-treat diseases that our products address. For example, a variety of our partnerships aim to educate patients about the distinct features of LEMS, which is often misdiagnosed as other neuromuscular diseases. Some of the organizations we work with include:

- The National Organization for Rare Disorders;
- The Mighty; and
- The Myasthenia Gravis Foundation of America.

As we expand our product and patient base, Catalyst remains focused on ensuring that each of our products, including FIRDAPSE®, FYCOMPA®, and AGAMREE®, are available and accessible to all patients who need them and that we are engaged in community outreach across all our products and patients.

To support patient advocacy groups and initiatives that improve the lives of those suffering from rare neuromuscular diseases, a formal process to review charitable requests has been established to identify and support requests from qualified non-profit organizations related to the patient communities we serve. For more information and application requirements, please email our Patient Engagement team at PatientEngagement@catalystpharma.com.

Patient Engagement Team

Our patient engagement team leads external communications with advocacy organizations and our communities. We seek and highly value community feedback and insights throughout all engagements. The mission of our patient engagement team is simple: to build and sustain trusting relationships with families and advocacy organizations to address rare disease issues and create opportunities to make a difference in patients' lives.

GUIDING PRINCIPLES

As outlined in our Patient Engagement Charter, to ensure that our relationships with patients and patient organizations are thoughtful and transparent, we rely on the following principles:

- We recognize and respect the autonomy of our advocacy partners and seek to reinforce their independence and integrity. We will not place our interests above theirs.
- We will not request or expect a patient organization to promote a Catalyst Pharmaceuticals product.
- We will be open and transparent about the objectives and scopes of any collaboration with patient organizations.
- We will respect and guard the privacy of all personal information and data we may receive from patients and patient organizations. We will only release information if given consent.
- We strongly encourage patient organizations to pursue and establish multiple funding sources.
- We will acknowledge Catalyst's support and sponsorships of such organizations.

Investigator-Sponsored Research

Catalyst is committed to advancing medical and scientific research to address the unmet needs of patients with rare, debilitating neuromuscular and neurological diseases. We participate in investigator-sponsored research ("ISR") to generate promising medical interventions. Specifically, ISR comprises clinical studies that are initiated and managed by non-pharmaceutical company researchers, such as individual investigators, institutions, collaborative study groups, and cooperative groups.

More information about our ISR requirements and how to submit a proposal can be found on our Investigator-Sponsored Research webpage. Additionally, for further questions about the process, or to discuss specific proposals, please contact us at: isr@catalystpharma.com.

ENVIRONMENT

Environment

Taking action on climate change is an opportunity for global collaboration, where both internal and external stakeholders are urging companies to take responsibility for their environmental footprint. With our Company's expanding global presence and the rise in ESG regulations, we recognize the importance of our role in supporting a sustainable future and being transparent about the current and potential impact of our operations.

We estimate that our direct environmental impact is relatively small, as we operate one corporate office and do not own or operate any manufacturing facilities. As such, our low volume and focused approach to distributing products is largely dependent on third-party suppliers and manufacturers. Although our impact is minimal, we continuously seek to monitor our corporate footprint through mindful operations and resource management. As outlined in the Environmental Strategy section, we are committed to initiating actionable steps to improve our environmental initiatives, reporting, and transparency for all stakeholders.

Our Environmental Strategy

Our commitment to environmental stewardship is underscored by our robust oversight mechanisms. In 2021, Catalyst established our Corporate Responsibility Steering Committee to oversee and evaluate Catalyst's current status on ESG issues. The committee meets regularly to keep our program updated with the latest climate-related regulations, establish initiatives and monitor next steps, and develop policies, strategies, and metrics to support those initiatives. With the guidance of this committee, we prioritize and develop appropriate environmental strategies and program objectives.

Moreover, our holistic approach to ESG oversight ensures that environmental concerns are considered at the highest level. The entire Board is dedicated to prioritizing environmental sustainability as a fundamental aspect of our corporate responsibility agenda (refer to the ESG Oversight section for further details).

OUR KEY FOCUS AREAS FOR PROGRESS IN 2023 AND BEYOND:

Identifying our priorities and developing a roadmap to enhance our current environmental program over the next 1-3 years.

Working to establish a structured and consistent data collection system across our departments, focusing on accurate and efficient data gathering, including those related to energy usage and GHG emissions calculations.

Advancing Climate-Related Disclosures

We understand that many recommended third-party disclosures, as well as those required as part of upcoming legislation, largely align with the recommendations of the Taskforce on Climate-Related Financial Disclosures ("TCFD"). To ensure we are adequately prepared to align with these recommendations and advance our disclosures to address stakeholder expectations, we are undertaking numerous preparedness activities. As we assess the evolving climate-related regulatory environment and continue to align our business strategies with our ESG priorities, we are actively addressing the following environmental considerations:

- Educating internal stakeholders, including the Corporate Responsibility Steering Committee, identified environmental operational owners, and select members of leadership, on suggested disclosures per the TCFD recommendations and how each aligns with our priorities as a company and the requirements of upcoming legislation.
- Conducting an analysis to identify climate-related risks and opportunities and outline mitigation strategies within our organization and value chain.
- Progressing towards measuring and reporting available information on our Scope 1 and 2 emission footprints, enabling us to establish measurable emissions reduction targets.

We believe these efforts will better prepare Catalyst to not only comply with upcoming regulatory requirements, but also allow our Company to progress ESG reporting and enhance transparency for our stakeholders.

Operational Footprint

Catalyst's only location of operation, our approximately 10,000 square foot corporate office with an average daily staff presence of approximately 20 employees, is located in a Leadership in Energy and Environmental Design ("LEED") Gold-certified green building. The building, including our office, has been designed, renovated, and operated in a way that promotes sustainable practices.

To that end, Catalyst operates with a relatively low environmental footprint. These efforts focus on optimizing energy efficiency, practicing water conservation, minimizing waste with recycling efforts, and ensuring the quality of the indoor environment. Some of the building's existing efforts include:

- **Energy Conservation:** The building has been awarded an ENERGY STAR® rating of 91 out of 100. Our state-of-the-art building automation system optimizes energy usage by controlling the building's HVAC system and exterior lighting. Occupancy sensors have been installed in interior restrooms and equipment rooms, effectively eliminating the need for lighting in unoccupied areas.
- **Waste Management:** The building has implemented a comprehensive recycling program covering a wide range of materials. Recycling containers have been installed in each tenant's office and an e-waste recycling program is hosted twice a year.
- **Water Conservation:** Sink aerators and low-flow fixtures have been installed in restrooms throughout the building. Additionally, rain gauge moisture sensors are integrated into the landscaping irrigation system and native and adaptive plants, which require minimal watering, were selected for the building exterior.
- **Ensuring the quality of indoor environment:** CO_2 sensors installed on air conditioning equipment maximize fresh air intake into the building while reducing the need to cool non-essential outside air. The building also implements an integrated pest management policy that reduces need for pesticides used inside building.

Emissions & Energy Management

We have been making progress to establish a structured system for collecting data efficiently across our various departments. This initiative has, and will continue to, enable us to gain better insights and control over our energy usage and other greenhouse gas emissions relevant to our business. We are continuing our efforts to measure and report available information on our Scope 1 and 2 emissions footprints, which will enable us to set measurable targets for reducing emissions in the future.

Given our current comparatively smaller organizational footprint, we infer that our primary sources of Scope 1 and 2 emissions stem from our daily operations and maintenance at the corporate office, and we will continue to monitor any changes as the organization grows. To enhance energy efficiency, our corporate office has collaborated with our building management to implement various technologies, including energy-efficient lighting fixtures and standard issued computers that are ENERGY STAR® certified.

Consistent with our environmental strategy and roadmap, Catalyst will continue to enhance the scope of our emissions and energy disclosure in forthcoming reporting cycles to provide transparency to our stakeholders and comply with the SEC climate disclosure rule.

Waste Management

Considering Catalyst outsources our manufacturing processes, our primary source of direct waste is from our corporate office. Due to the predominant use of electronics in our operations, we generate minimal paper waste. Catalyst actively supports the waste management and recycling policies established by our LEED-certified building, which includes participating in a recycling program that collects office paper, cardboard, plastic, glass, lightbulbs, and batteries. By doing this, a majority of the building's waste is diverted from landfills.

Catalyst also offers a program that enables employees to acquire obsolete electronics for personal use, such as laptops, iPads, and printers, to divert from waste and prevent the dispose of potentially harmful materials into the environment.

While Catalyst does not operate any manufacturing facilities, we remain responsible for the packaging of our products in preparation for distribution. We adhere to FDA regulations to ensure that no recycled materials are used in packaging that has direct contact with our products.

Water Management

Similarly, direct water usage at Catalyst is minimal, primarily dedicated to sustaining operations at our corporate office. Within a LEED certified building, our corporate office implemented several measures to help us reduce water consumption, such as sink aerators and low flow fixtures in bathrooms and rain gauge moisture sensors on landscaping irrigation systems.

GOVERNANCE

Governance

Corporate Governance

Catalyst understands the important role ESG plays in sound corporate governance, as it facilitates our ability to deliver long-term sustainable value creation for our shareholders and all stakeholders. Our comprehensive governance policies reinforce Catalyst's values for ethical business conduct and set high standards for our employees, Officers, and Directors. We believe our corporate governance practices establish robust oversight frameworks, supporting our Company in advancing our growth strategy while identifying and mitigating risks effectively.



2023 Board Composition

Catalyst's Board of Directors is responsible for the oversight of our business management strategy and is expected to adhere to the high standards outlined in our respective committee charters and Code of Business Conduct and Ethics. These guidelines, which are underpinned by our key values, emphasize our commitment to sound and ethical corporate governance practices.

Our Board of Directors has seven members, most of whom are independent and serve on various committees.[9] Our member selection process is designed to seek Board members with the appropriate expertise and commitment to ESG to drive Catalyst's ESG strategy, while also confirming no conflicts of interest exist among prospective Board members. We believe the diversity of expertise and backgrounds of our Board members fosters decisions that both maximize our market position, as well as our ability to develop innovative solutions that serve our patients and therefore, we consider diversity as one of several factors with respect to director nominations. When recommending nominations to our Board, the Corporate Governance and Nominating Committee ensures candidates add value to our Board with a variety of opinions, perspectives, backgrounds, experience, skills, and expertise.[10]

On December 31, 2023, Patrick J. McEnany, Catalyst's Co-Founder and then-President and Chief Executive Officer retired from that role with the Company and was succeeded by Richard J. Daly, a long-term Catalyst Board member with extensive knowledge of our Company, growth strategy, and the pharmaceuticals industry. Mr. McEnany and Mr. Daly both remain key members of our Board of Directors, with Mr. McEnany continuing to hold the position of Chairman of the Board of Directors. Ms. Tamar Thompson joined our Board of Directors in May 2023 in preparation for the departure of Philip H. Coelho in August of 2023. We are excited about the experience and perspectives Ms. Thompson brings to our Board and we look forward to the continuation of strong top-level leadership from this group.

9. Note: Data as of April 1, 2024.
10. For detailed descriptions of Board expertise, refer to our Board of Directors webpage.

Patrick J. McEnany
Co-Founder and Chairman

Over 30 years of experience in the pharmaceutical industry, serving as the Chief Executive Officer and director of Catalyst since its formation in January 2002.

- Catalyst Pharmaceuticals
- Jackson Memorial Hospital Foundation
- Royce Laboratories
- National Association of Pharmaceutical Manufacturers

Richard J. Daly
President and Chief Executive Officer

Significant experience within the pharmaceuticals industry, specifically sales management of pharmaceutical products for orphan/rare diseases.

- AstraZeneca PLC
- BeyondSpring, Inc.
- CARsgen Therapeutics Holdings Ltd.
- Neuralstem, Inc.
- Opiant Pharmaceuticals, Inc.
- Synergy Pharmaceuticals, Inc.

Donald A. Denkhaus
Director

Audit (Chair); Corporate Governance and Nominating; Independent

Extensive financial experience and previously served as director of two pharmaceutical companies.

- Arthur Andersen LLP
- Noven Pharmaceuticals, Inc.
- Nuovo Biologics, LLC
- The Kitchen, LLC

Molly Harper
Director

Compensation; Corporate Governance and Nominating; Independent

Significant experience in pharmaceutical company operations overseeing the development, launch and commercialization of several products, some of which are used to treat orphan/rare diseases.

- Akcea Therapeutics, Inc.
- PreciseDx
- Relmada Therapeutics, Inc.
- Sanofi Genzyme
- Synlogic, Inc.
- Merck & Co., Inc.
- UBS

Charles B. O'Keeffe
Lead Independent Director

Audit; Compensation; Corporate Governance and Nominating; Independent

Extensive history of leadership roles in the pharmaceutical industry.

- Pharmaceutical Services, Inc.
- Reckitt Benckiser Pharmaceuticals, Inc.
- UN Commission on Narcotic Drugs
- Virginia Commonwealth University School of Medicine
- Washington Reference Laboratories
- White House Advisor
- World Health Assembly

Tamar Thompson
Director

Corporate Governance and Nominating (Chair); Audit; Independent

Experience in health policy and government affairs, and focuses on rare diseases in current position.

- Alexion Pharmaceuticals /AstraZeneca Rare Disease
- Bristol-Myers Squibb Company
- ADVI
- Kimbell and Associates
- Avalere Health
- Avidity Biosciences, Inc.

David S. Tierney, MD
Director

Compensation (Chair); Corporate Governance and Nominating; Independent

Business leadership and pharmaceutical industry experience.

- Aramis Biosciences, Inc.
- Bimeda, Inc.
- BioPharmX Corp.
- Biovail Technologies Ltd.
- Icon Bioscience, Inc.
- Zevra Therapeutics, Inc.
- Oceana Therapeutics, Inc.
- Pharma Two B. Ltd.
- Valera Pharmaceuticals, Inc.

To ensure our Board of Directors remains equipped to serve our shareholders and make strong decisions that further the success of our business, we regularly review Board membership, accounting for various factors such as the evolving business landscape and our growth strategy. The Corporate Governance and Nominating Committee periodically reviews the structure, function, membership, and charters of the committees of the Board, and recommends to the Board the adoption of any changes. This Committee also establishes criteria and processes for an annual performance self-evaluation by the Board, each committee of the Board, and each director. The Committee reviews, summarizes, and reports the results of such evaluations to the Board. We have no established term limits or mandatory retirement policies for our Board members as our refreshment protocols are effective, and those with greater tenure often offer greater insight and perspective related to the objectives in focus.

Our Board is committed to serving in Catalyst's best interest and operating according to the highest standards and most updated regulatory requirements. The Board of Directors meets at least quarterly and in 2023, there was over 75% attendance at all Board meetings. The three Board committees meet regularly and had an attendance rate over 75% for all committee meetings last year. High attendance at each meeting demonstrates the Board's close involvement with pertinent business and regulatory matters.

Our Board of Directors is comprised of three committees, whose more detailed responsibilities are outlined in their respective committee charters, which were recently updated to reflect our evolving business and ensure the delegation of responsibilities remains appropriate:

COMPENSATION COMMITTEE

The Compensation Committee is responsible for decisions related to compensation of the Company's executives, recommending and approving compensation plans for Company employees, and producing an annual report on executive compensation.

AUDIT COMMITTEE

The Audit Committee oversees the accounting and integrity of financial reporting, compliance with legal and regulatory requirements, performance of the Company's internal audit function, and audits of the Company's financial statements, including appointment of independent auditors. Responsibilities of the Committee include stockholder reporting, developing risk management structures, and ensuring legal, ethical, and regulatory compliance.

CORPORATE GOVERNANCE AND NOMINATING COMMITTEE

The Corporate Governance and Nominating Committee assists the Board in identification and selection of qualified Board member candidates, development and recommendation of corporate governance guidelines, and oversight of evaluation of the Board.

Executive Incentives

At Catalyst, we aim to attract and retain high quality talent who are committed to achieving our mission while creating value for our shareholders and other key stakeholders. To do so, we seek to balance near-term financial and operational performance with long-term success. As outlined in our 2023 Proxy Statement, we structure our compensation plans to incentivize long-term value creation. Our competitive compensation package includes a combination of base pay, bonus compensation, deferred compensation, retirement and stock incentives, and additional long-term incentive compensation aimed to attract, retain, and motivate critical personnel to achieve our mission and exceed our goals.

Oversight of our executive compensation decisions lies with the Compensation Committee of the Board of Directors. This committee meets regularly to make informed decisions considering fair payment practices that align with Catalyst's long-term strategic goals. To do so, the Compensation Committee utilizes data and analysis on market trends from an independent compensation consultant to ensure our compensation practices remain equitable, reasonable, and competitive relative to industry standards.

When determining executive compensation, we consider several factors including net product revenue, net income, completion of significant acquisitions, and quality and compliance performance. These considerations correlate with the various corporate goals and objectives associated with executive cash bonuses. For example, cash bonuses have been tied to performance against revenue targets, quality and compliance outcomes, and the release of our inaugural ESG Report in 2023. Our Compensation Committee will continue to hold executives accountable by tying executive compensation to measurable and attainable goals that propel our Company forward.

Shareholder Rights

Catalyst values input from our shareholders and engages with shareholders frequently. Catalyst's Annual Meeting of Stockholders provides a forum for opinions to be voiced and proposals discussed and voted upon. Each holder of common stock is entitled to one vote on all matters on which stockholders generally are entitled to vote including the election of Board members, which occurs annually. Additionally, as part of the Annual Meeting process, the Annual Report and Proxy Statement are provided to update all on business matters.

Going forward, we will continue to solicit opinions and proactively engage with stockholders and key stakeholders to ensure all formal and informal proposals are considered as long as they reasonably enhance value creation and strengthen Catalyst's ability to serve patients.

Risk Management

Catalyst has a comprehensive and cross-functional risk management program designed to protect patients, employees, shareholders, and our broader business strategy. We have established policies, processes, and personnel to identify, assess, and mitigate risks to ensure our business remains resilient in the evolving business environment.

Risk Oversight

Our Board of Directors is responsible for overseeing risk management strategies and processes at Catalyst. Our Board members have diverse experience associated with risk management, equipping them to oversee our risk management program effectively. Our risk management strategy is implemented by Committees of the Board of Directors, senior executives, and cross-functional operations managers. Each group has various responsibilities associated with addressing risks and regulatory requirements to ensure Catalyst's long-term success and sustainability.

Risk Management Responsibilities

BOARD OF DIRECTORS

Risk Oversight

- Review risk assessment and ensure risk management plans address identified risks.
- Address additional risk management concerns, including mitigation and remediation plans.
- Oversight of the Company's internal audit function, including internal controls over financial reporting, to preserve the integrity of financial statements.
- Appoint, compensate, retain, and oversee the work of independent auditors.

SENIOR EXECUTIVES (C-Suite and Vice Presidents)

Risk Oversight Strategy Implementation

- Ensure that risk management policies and procedures are implemented as determined by the Board of Directors in conjunction with independent auditors.
- Serve as a bridge for communication between managers and the Board of Directors.

MANAGERS & INDIVIDUAL CONTRIBUTORS

Day-to-Day Risk Management Activities

- Day-to-day risk management based on job duties including facilitation of internal controls.
- Identification and escalation of any potential operational barriers in implementing internal controls and communicating status to executives.

INDEPENDENT AUDITOR

- Perform audit of the Company's annual financial statements, expressing an opinion as to the conformity of such annual financial statements with generally accepted accounting principles.
- Review the Company's quarterly financial statements to ensure regulatory compliance.
- Report findings to the Audit Committee of the Board of Directors at least quarterly.

Catalyst performs an annual risk assessment, as highlighted in our Form 10-K to identify material risks to our business. Conducting this risk assessment ensures that we have a comprehensive understanding of the risk factors that have the potential to impact our business. Some of the risks we consider in our assessment include those related to marketing of approved products, development of products in the pipeline and indications, government regulation, and intellectual property.

In addition, Catalyst operations are assessed for corruption risks in an ongoing fashion to ensure we continue to operate in an ethical and responsible manner. This includes our ongoing activities and interactions with patients and prescribers and also our interactions with entities internationally who are screened individually for corruption risks. We believe our annual risk assessment process and our ongoing risk assessment activities together allow our Company to identify the risks most material to our business and position our Company to prepare to mitigate the potential impact of these risks, thus strengthening the resilience of our Company.

The Audit Committee, supported by our independent auditor, is responsible for risk identification, mitigation, and communication of risks to the Board of Directors. This Committee manages the implementation of internal risk controls, which Catalyst has in place to address financial, operational, and regulatory risks. These controls ensure financial statements are prepared accurately and according to applicable regulations. The Audit Committee and management discuss Catalyst's risk management program regularly, ensuring accountability and timely response to identified risks.

Regulatory Preparedness

We recognize the importance of adhering to regulations to safeguard our business. Accordingly, we proactively ensure that our operational processes align with regulatory requirements. The FDA has important, comprehensive regulations regarding the development, release, and manufacturing of drugs. To ensure we meet all FDA regulations, we follow good laboratory practice ("GLP") during pre-clinical drug development, good clinical practices ("GCP") during clinical trials, and good manufacturing practices ("GMP") during the manufacturing state of our products. We are confident in our adherence to these regulations and welcome FDA inspections and further studies.

In addition to regulations from the FDA and certain state regulatory agencies, we are also subject to a variety of foreign regulations governing clinical trials and the marketing of other products such as the European Medicines Agency and the European Commission. Regulatory requirements governing the conduct of clinical trials, marketing authorization, pricing, and reimbursement vary from country to country. However, across all countries, we will only be permitted to commercialize our products if the appropriate regulatory agency is satisfied that we have presented adequate evidence of safety, quality, and efficacy.

Due to our recent acquisition of FYCOMPA®, a Schedule III controlled substance, we are also required to adhere to Drug Enforcement Administration ("DEA") regulations and obtain additional state-controlled substance registrations. Through our control procedures, we remain compliant with the regulations associated with the manufacturing, storage, distribution, and dispense of our product, including those associated with physician prescription procedures and limitations on prescription refills. One of the key components of this is that the third-party facilities who perform our clinical and commercial manufacturing, distribution, and dispensing of FYCOMPA® are required to remain compliant with applicable DEA registrations, state licenses, and all other regulatory requirements. The DEA and the relevant state agencies periodically inspect facilities for compliance with its rules and regulations.

Data Privacy and Security

We recognize the critical importance of developing, implementing, and maintaining robust cybersecurity measures to safeguard our information systems and protect the confidentiality, integrity, and availability of our Company and patient data. We integrate cybersecurity risk management into our broader risk management framework and have comprehensive data protection policies, systems, and initiatives that protect patient, provider, and employee data. All Catalyst personnel have an obligation to protect this information as outlined in the Code of Business Conduct and Ethics.

Our Board of Directors is responsible for oversight of cybersecurity risks and ensuring effective governance in managing risks associated with cybersecurity threats. Primary responsibility for assessing, monitoring, and managing our

cybersecurity risks rests with our Chief Legal and Compliance Officer (CLCO), Chief Operating Officer (COO), and Information Technology (IT) personnel. The CLCO and the COO lead an internal cybersecurity team in which the CFO regularly participates and regular updates are provided to our CEO on activities related to monitoring and managing cybersecurity risks and incidents. This ensures that the highest levels of management are kept abreast of Catalyst's cybersecurity posture and are prepared potential risks facing our Company. Significant cybersecurity matters and strategic risk management decisions are escalated to the Board of Directors, ensuring that they have comprehensive oversight and can provide guidance on critical cybersecurity issues.

Our risk management team works closely with our IT team to continuously evaluate and address cybersecurity risks. As part of this process, we engage with external experts to evaluate and test our risk management systems. This collaboration includes regular audits, threat assessments, and consultation on security enhancements that ensure our practices remain at the forefront of industry best practices. We also conduct thorough security assessments of all third-party providers prior to and throughout engagement via quarterly assessments by our CLCO and COO, and on an ongoing basis by our IT professionals, to ensure compliance with our cybersecurity standards.

Our Privacy Policy outlines the type of patient information we collect, how we use it, and the steps we take to protect personal information from loss, misuse, alteration, or destruction. Unauthorized use or distribution of information maintained by Catalyst is prohibited, and all Catalyst personnel are required to maintain the confidentiality of material non-public information as outlined in signed agreements. We continue to monitor cybersecurity best practices and update our policies and procedures as needed to ensure the security of both patient and Company information.

In 2023, we had zero cybersecurity incidents and did not encounter any cybersecurity challenges that have materially impaired our operations or financial standing. For additional cybersecurity disclosures, refer to our Form 10-K.

Indexes & Performance Data

Performance Data

GENERAL DATA

Metric	Unit	2021	2022	2023
Revenue	Dollars ($)	**140,833,000**	**214,203,000**	**398,204,000**
Total Employees[1]	Number	75.5	75.0	164.0
Full-Time Employees[2]	Number	73.5	73.0	162.0
Part-Time Employees[3]	Number	2.0	2.0	2.0
Contracted Workers[4]	Number	0.0	0.0	0.0
Average Executives Employee Headcount[5]	Number	10.0	9.5	11.0
Average Mid Level Managers Employee Headcount[5]	Number	12.5	15.5	29.0
Average Professionals Employee Headcount[5]	Number	34.5	31.0	68.0
Average Sales Employee Headcount[5]	Number	16.0	16.0	48.0
Average Administrative Employee Headcount[5]	Number	2.5	3.5	8.0

ENVIRONMENT DATA

Metric	Unit	2021	2022	2023
Waste				
Waste Generated[6]	Metric tons	-	-	2.1
Waste Diverted From Disposal[6]	Metric tons	-	-	0.3
Waste Directed to Disposal[6]	Metric tons	-	-	1.8

1. Accounted for on 12/31/2023, includes full-time and part-time employees.
2. Accounted for on 12/31/2023, includes employees who work 40 hours per week.
3. Accounted for on 12/31/2023, includes employees who work less than 40 hours per week.
4. Accounted for on 12/31/2023, includes employee type of consultant or contractor.
5. All employees classified according to the U.S Equal Employment Opportunity Commission EEO-1 Job Classification Guide.
6. Calculated based on Catalyst's prorata share of square footage for office building and waste per building records.

SOCIAL DATA

Metric	Unit	2021	2022	2023
Our Employees				
Talent Attraction				
New Hires	Number	-	10.0	81.0
Average Employee Length of Service[7]	Years	-	4.1	1.5
Voluntary Turnover Rate[8]				
Voluntary Turnover Rate All Employees	Percentage (%)	9.3%	10.6%	6.1%
Voluntary Turnover Rate Executives	Percentage (%)	0.0%	10.5%	18.2%
Voluntary Turnover Rate Mid Level Managers	Percentage (%)	8.0%	6.5%	0.0%
Voluntary Turnover Rate Professionals	Percentage (%)	5.8%	19.4%	5.9%
Voluntary Turnover Rate Sales	Percentage (%)	18.8%	0.0%	6.3%
Voluntary Turnover Rate Administrative	Percentage (%)	40.0%	0.0%	12.5%
Voluntary Turnover Rate All Employees	Number	7.0	8.0	10.0
Voluntary Turnover Rate Executives	Number	0.0	1.0	2.0
Voluntary Turnover Rate Mid Level Managers	Number	1.0	1.0	0.0
Voluntary Turnover Rate Professionals	Number	2.0	6.0	4.0
Voluntary Turnover Rate Sales	Number	3.0	0.0	3.0
Voluntary Turnover Rate Administrative	Number	1.0	0.0	1.0
Involuntary Turnover Rate[9]				
Involuntary Turnover Rate All Employees	Percentage (%)	4.0%	2.7%	3.0%
Involuntary Turnover Rate Executives	Percentage (%)	0.0%	0.0%	0.0%
Involuntary Turnover Rate Mid Level Managers	Percentage (%)	8.0%	0.0%	0.0%
Involuntary Turnover Rate Professionals	Percentage (%)	2.9%	6.5%	5.9%
Involuntary Turnover Rate Sales	Percentage (%)	6.3%	0.0%	2.1%
Involuntary Turnover Rate Administrative	Percentage (%)	0.0%	0.0%	0.0%
Involuntary Turnover Rate All Employees	Number	3.0	2.0	5.0
Involuntary Turnover Rate Executives	Number	0.0	0.0	0.0
Involuntary Turnover Rate Mid Level Managers	Number	1.0	0.0	0.0

7. Average across all Catalyst employees, difference from 2022 to 2023 due to 81 new hires.
8. All employees classified according to the U.S Equal Employment Opportunity Commission EEO-1 Job Classification Guide.
9. All employees classified according to the U.S Equal Employment Opportunity Commission EEO-1 Job Classification Guide.

SOCIAL DATA, CONTINUED

Involuntary Turnover Rate[9]				
Involuntary Turnover Rate Professionals	Number	1.0	2.0	4.0
Involuntary Turnover Rate Sales	Number	1.0	0.0	1.0
Involuntary Turnover Rate Administrative	Number	0.0	0.0	0.0
Diversity & Inclusion				
Incidents of Discrimination	Number	0	0	0
Gender				
Women Representation of Employees	Percentage (%)	57.0%	61.0%	56.0%
Men Representation of Employees	Percentage (%)	43.0%	39.0%	43.0%
Not Disclosed (All Employees)	Percentage (%)	0.0%	0.0%	0.0%
Women Representation in Senior Management Positions[10]	Percentage (%)	30.0%	33.3%	46.7%
Men Representation in Senior Management Positions[11]	Percentage (%)	70.0%	67.0%	53.3%
Age				
Employees less than 30 years old	Percentage (%)	-	-	4.3%
Employees between 30 and 50 years old	Percentage (%)	-	-	46.9%
Employees greater than 50 years old	Percentage (%)	-	-	48.8%
Race/Ethnicity (All Employees)				
Total Employees Represented by Minority Groups	Percentage (%)	40.0%	44.0%	39.6%
White	Percentage (%)	60.0%	56.0%	69.4%
Asian	Percentage (%)	9.3%	10.5%	13.4%
Hispanic/Latino	Percentage (%)	25.3%	26.3%	16.5%
Black or African American	Percentage (%)	4.0%	6.6%	7.3%
Other Ethnicities[12]	Percentage (%)	1.3%	1.3%	2.4%
Not disclosed	Percentage (%)	0.0%	0.0%	0.0%

10. Senior Management refers to Sr. VP and above.
11. Senior Management refers to Sr. VP and above.
12. Includes two or more races, American Indian or Alaska Native, and Native Hawaiian or Pacific Islander.

SOCIAL DATA, CONTINUED

Race/Ethnicity (Senior Management)				
Senior Management Represented by Minority Groups	Percentage (%)	40.0%	44.0%	32.5%
White	Percentage (%)	60.0%	56.0%	67.5%
Asian	Percentage (%)	30.0%	33.0%	15.0%
Hispanic/Latino	Percentage (%)	10.0%	11.0%	12.5%
Black or African American	Percentage (%)	0.0%	0.0%	5.0%
Other Ethnicities[13]	Percentage (%)	0.0%	0.0%	0.0%
Not disclosed	Percentage (%)	0.0%	0.0%	0.0%
Human Rights				
Incidents of Violations Involving Rights of Indigenous Peoples	Number	0	0	0
Operations at Risk for Child Labor[14]	Percentage (%)	0.0%	0.0%	0.0%
Employee Training and Development				
New Hires who Complete Code of Conduct Training[15]	Percentage (%)	-	100%	100%
Employees Receiving Regular Performance Reviews[16]	Percentage (%)	-	100%	100%
Health and Safety				
Work-related Injuries	Number	0.0	0.0	0.0
Work-related Ill Health	Number	0.0	0.0	0.0
Our Patients and Product				
Patients and Product				
Patients Treated[17]	Number	> 1,000	> 1,000	~25,000
Drugs in Portfolio	Number	1.0	1.0	3.0
Drugs in Research and Development[18]	Number	1.0	1.0	2.0
Number of Diseases Treated with Drugs on Market[19]	Number	-	-	4.0

13. Includes two or more races, American Indian or Alaska Native, and Native Hawaiian or Pacific Islander
14. Based on assessment of all operating Catalyst facilities.
15. Training for this topic in 2023 was assigned to all new hires. Refer to 2022 ESG Report for data on training that was assigned to all Catalyst employees.
16. Performance reviews conducted at least annually for all Catalyst employees.
17. Estimate for FIRDAPSE® and FYCOMPA® based on actuals and claims data for the total patients who accessed one of our drugs at least once in 2023.
18. Research activities we are conducting for FIRDAPSE® and AGAMREE®
19. Includes LEMS, DMD, and two forms of Epilepsy

SOCIAL DATA, CONTINUED

Number of Diseases Treated with Drugs in Research[20]	Number	-	-	5.0
Products Assessed for Safety[21]	Percentage (%)	100.0%	100.0%	100.0%
Recalls Issued	Number	0.0	0.0	0.0
Total Units Recalled	Number	-	-	0.0
Number of enforcement actions taken in response to violations of Good Manufacturing Practices (GMP) or equivalent standards	Number	0.0	0.0	0.0
Total monetary losses as a result of legal proceedings associated with clinical trials in developing countries	Dollars ($)	0.0	0.0	0.0
Fatalities associated with products reported in the FDA Adverse Event Reporting System[22]	Number	42.0	29.0	22.0
Actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products	Number	0.0	0.0	0.0
Supply Chain				
Percentage of entity's Tier 1 suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit programme or equivalent	Percentage (%)	-	29%	63%
Percentage of entity's Tier 1 suppliers' facilities that have achieved ISO 140001 or HAZWOPER certification[23]	Percentage (%)	-	-	63%
Frequency of Supplier Training[24]	Number	-	Annually	Annually
Communities				
Philanthropy				
Charitable Donations[25]	Dollars ($)	-	$5,092,000	$5,900,000

20. Includes LEMS, DMD, two forms of epilepsy and an ongoing trial in Becker Muscular Dystrophy by our ultimate licensor to which we have rights.
21. All CPRX products are subject to quality testing prior to patient use as aligned with our standards and the requirements of regulatory agencies.
22. All fatalities are not related to Catalyst product use. Please note that 2021 fatalities have been restated with more accurate data using the FAERS database.
23. 4 out of 8 Tier 1 suppliers are ISO 14001 certified, 1 Tier 1 supplier achieved HAZWOPER certification
24. All new vendors are trained before start of work/services. Subsequently PV team ensures vendors have process in place for annual refresher training.
25. Charitable contributions to 501(c)(3) organizations for patient support, patient advocacy, and medication education.

GOVERNANCE DATA

Metric	Unit	2021	2022	2023
Board Composition				
Board Members	Number	7.0	7.0	7.0
Board Member Average Term Duration	Years	12.3	13.3	11.3
Board of Directors Average Age	Years	67.6	68.6	65.3
Board of Directors Gender Representation[26]	Percentage (%)	14.3%	14.3%	28.6%
Board of Directors Ethic Diversity Representation[27]	Percentage (%)	0.0%	0.0%	14.3%
Independent Directors	Number	6	6	5
Board Member Diversity				
Female Board Members	Number	1.0	1.0	2.0
Male Board Members	Number	6.0	6.0	5.0
White	Number	6.0	6.0	6.0
Asian	Number	0.0	0.0	0.0
Hispanic/Latino	Number	0.0	0.0	0.0
Black or African American	Number	0.0	0.0	1.0
Other Ethnicities	Number	0.0	0.0	0.0
Not disclosed	Number	0.0	0.0	0.0
Corruption & Bribery				
Incidents of Corruption	Number	0.0	0.0	0.0
Total monetary losses as a result of legal proceedings associated with corruption and bribery	Dollars ($)	$0.00	$0.00	$0.00
Percentage of governance body members that the organization's anti-corruption policies have been communicated to	Percentage (%)	-	-	100%
Percentage of employees that the organization's anti-corruption policies have been communicated to	Percentage (%)	-	-	100%
Ethical Marketing				
Incidents of non-compliance concerning product information and labeling	Number	0.0	0.0	0.0
Total monetary losses as a result of legal proceedings associated with false marketing claims	Dollars ($)	$0.00	$0.00	$0.00
Incidents of non-compliance concerning marketing communications	Number	0.0	0.0	0.0

26. Percentage of Board that identifies as female based on Nasdaq Rule 5605(f) and related instructions.
27. Based on demographic background as it is used in Nasdaq Rule 5605(f) and related instructions.

SUSTAINABILITY ACCOUNTING STANDARDS BOARD

BIOTECHNOLOGY PHARMACEUTICALS (HC:BP)

Key Topic	Metric	Category	Unit of Measure	SASB Code	Disclosure Reference
SASB Healthcare : Biotechnology Pharmaceuticals (HC:BP)					
Safety of Clinical Trial Participants	Discussion, by region, of management process for ensuring quality and patient safety during clinical trials	Discussion & Analysis	n/a	HC-BP-210a.1	Patient Safety
Safety of Clinical Trial Participants	Number of inspections related to clinical trial management and pharmacovigilance that resulted in: (1) entity voluntary remediation or (2) regulatory or administrative actions taken against the entity	Quantitative	Number	HC-BP-210a.2	See footnote[28]
Safety of Clinical Trial Participants	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	Quantitative	Reporting currency	HC-BP-210a.3	Performance Data
Access to Medicines	Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	Discussion & Analysis	n/a	HC-BP-240a.1	See footnote[29]
Access to Medicines	List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	Discussion & Analysis	n/a	HC-BP-240a.2	See footnote[30]
Affordability & Pricing	Percentage change in: (1) weighted average list price and (2) weighted average net price across product portfolio compared to reporting period year	Quantitative	Percentage (%)	HC-BP-240b.2	Additional Efforts to Optimize Coverage and Access[31]
Affordability & Pricing	Percentage change in: (1) list price and (2) net price of product with largest increase compared to reporting period year	Quantitative	Percentage (%)	HC-BP-240b.3	Additional Efforts to Optimize Coverage and Access[31]
Drug Safety	Products listed in any public medical product safety or adverse event alert database	Discussion & Analysis	n/a	HC-BP-250a.1	Performance Data
Drug Safety	Number of fatalities associated with products	Quantitative	Number	HC-BP-250a.2	Performance Data
Drug Safety	(1) Number of recalls issued, (2) total units recalled	Quantitative	Number	HC-BP-250a.3	Performance Data
Drug Safety	Total amount of product accepted for takeback, reuse, or disposal	Quantitative	Metric tonnes (t)	HC-BP-250a.4	Supply Chain Management[32]
Drug Safety	Number of enforcement actions taken in response to violations of Good Manufacturing Practices (GMP) or equivalent standards, by type	Quantitative	Number	HC-BP-250a.5	Performance Data
Counterfeit Drugs	Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting	Discussion & Analysis	n/a	HC-BP-260a.1	Counterfeit Drugs
Counterfeit Drugs	Discussion of process for alerting customers and business partners to of potential or known risks associated with counterfeit products	Discussion & Analysis	n/a	HC-BP-260a.2	Counterfeit Drugs

28. Catalyst was not involved in any inspections that resulted in entity voluntary remediation or regulatory or administrative actions taken against the entity.
29. Catalyst does not operate in high priority countries as defined by the Access to Medicines Index. FIRDAPSE® is approved to treat LEMS which is not a high priority disease as defined by the Access to Medicines Index.
30. Catalyst does not have a list of products authorized for sale and available on the WHO List of Prequalified Medicinal Products.
31. As Catalyst's product portfolio expands, we will focus on providing general updates on our policies and practices to maximize access and affordability for patients. Additional updates on Catalyst's product pricing may be provided through press releases, SEC filings, and quarterly earnings.
32. Catalyst is in the process of measuring total amount of product accepted for takeback, reuse, or disposal.

SUSTAINABILITY ACCOUNTING STANDARDS BOARD, CONTINUED

BIOTECHNOLOGY PHARMACEUTICALS (HC:BP)

Counterfeit Drugs	Number of actions that led to raids, seizure, arrests, or filing of criminal charges related to counterfeit products	Quantitative	Number	HC-BP-260a.3	Performance Data
Ethical Marketing	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	Quantitative	Reporting currency	HC-BP-270a.1	Performance Data
Ethical Marketing	Description of code of ethics governing promotion of off-label use of products	Discussion & Analysis	n/a	HC-BP-270a.2	Ethical Marketing
Employee Recruitment, Development & Retention	Discussion of talent recruitment and retention efforts for scientists and research and development personnel	Discussion & Analysis	n/a	HC-BP-330a.1	Talent Attraction & Retention
Employee Recruitment, Development & Retention	(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) midlevel managers, (c) professionals, and (d) all others	Quantitative	Percentage (%)	HC-BP-330a.2	Performance Data
Supply Chain Management	Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third party audit programs for integrity of supply chain and ingredients	Quantitative	Percentage (%)	HC-BP-430a.1	Supplier Training and Upholding Standards
Business Ethics	Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery	Quantitative	Reporting currency	HC-BP-510a.1	Performance Data
Business Ethics	Description of code of ethics governing interactions with health care professionals	Discussion & Analysis	n/a	HC-BP-510a.2	Business Ethics & Transparency

Activity Metric	Category	Unit of Measure	SASB Code	Disclosure Reference
Number of Patients Treated	Quantitative	Number	HC-BP-000.A	Performance Data
Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3)	Quantitative	Number	HC-BP-000.B	Growing a Diversified Portfolio

Global Reporting Initiative

Catalyst Pharmaceuticals has reported the information cited in this GRI content index for the period from January 1, 2023 to December 31, 2023 with reference to the GRI Standards.

GRI Indicator	Description	Disclosure Reference
The organization and its reporting practices		
2-1	Organizational Details	About Catalyst Pharmaceuticals
2-2	Entities included in the organization's sustainability reporting	About this Report
2-3	Reporting period, frequency and contact point	About this Report
Activities and workers		
2-6	Activities, value chain and other business relationships	About Catalyst Pharmaceuticals
2-7	Employees	Our Employees
2-8	Workers who are not employees	Performance Data
Governance		
2-9	Governance structure and composition	Corporate Governance; Proxy p. 9-16
2-10	Nomination and selection of the highest governance body	Proxy p. 9-16
2-11	Chair of the highest governance body	Board Composition; Proxy p. 9
2-12	Role of the highest governance body in overseeing the management of impacts	Board Composition; Proxy p. 12-16, 27-29
2-13	Delegation of responsibility for managing impacts	Proxy p. 12-16, 27-29
2-14	Role of the highest governance body in sustainability reporting	ESG Oversight & Business Ethics
2-15	Conflicts of interest	ESG Oversight & Business Ethics; Proxy p. 48
2-16	Communication of critical concerns	ESG Oversight & Business Ethics; Proxy p. 12-13
2-17	Collective knowledge of the highest governance body	Board Composition; Proxy p. 9-12
2-18	Evaluation of the performance of the highest governance body	Board Composition; Proxy p. 14-15, 30
2-19	Remuneration policies	Executive Incentives, Proxy p. 17-38
2-20	Process to determine remuneration	Executive Incentives, Proxy p. 17-38
2-21	Annual total compensation ratio	Proxy p. 42
Strategy, policies, and practices		
2-22	Statement on sustainable development strategy	CEO Letter
2-23	Policy commitments	ESG Oversight & Business Ethics; Human Rights
2-24	Embedding policy commitments	ESG Oversight & Business Ethics; Human Rights
2-25	Processes to remediate negative impacts	Whistleblower Protections
2-26	Mechanisms for seeking advice and raising concerns	Whistleblower Protections
2-27	Compliance with laws and regulations	Regulatory Preparedness
2-28	Membership associations	Industry Engagement and Advocacy
Stakeholder engagement		
2-29	Approach to stakeholder engagement	Materiality Assessment
2-30	Collective bargaining agreements	Form 10-K p. 34
Disclosures on material topics		
3-1	Process to determine material topics	Materiality Assessment
3-2	List of material topics	Materiality Assessment
3-3	Management of material topics	Materiality Assessment

GRI Indicator	Description	Disclosure Reference
Economic performance		
201-1	Direct economic value generated and distributed	Form 10K > page 56-69
201-3	Defined benefit plan obligations and other retirement plans	Form 10K > page 34
Anti-corruption		
205-1	Operations assessed for risks related to corruption	Risk Management
205-2	Communication and training about anti corruption policies and procedures	Business Ethics & Transparency
205-3	Confirmed incidents of corruption and actions taken	Performance Data
Anti-competitive behavior		
206-1	Legal actions for anti-competitive behavior, anti trust, and monopoly practices	Performance Data
Employment		
401-1	New employee hires and employee turnover	Performance Data
401-2	Benefits provided to full-time employees that are not provided to temporary or parttime employees	Employee Benefits and Incentives
Occupational health and safety		
403-6	Promotion of worker health	Employee Health & Safety
403-9	Work-related injuries	Performance Data
403-10	Work-related ill health	Performance Data
Training and education		
404-2	Programs for upgrading employee skills and transition assistance programs	Employee Training and Development
404-3	Percentage of employees receiving regular performance and career development reviews	Employee Engagement and Satisfaction
Diversity and equal opportunity		
405-1	Diversity of governance bodies and employees	Performance Data
Non-discrimination		
406-1	Incidents of discrimination and corrective actions taken	Performance Data
Child labor		
408-1	Operations and suppliers at significant risk for incidents of child labor	Performance Data, Human Rights
Rights of indigenous people		
411-1	Incidents of violations involving rights of indigenous peoples	Performance Data
Local communities		
413-1	Operations with local community engagement, impact assessments, and development programs	Community Involvement
Customer health and safety		
416-1	Assessment of the health and safety impacts of product and service categories	Drug Safety
416-2	Incidents of non-compliance concerning the health and safety impacts of products and services	Performance Data
Marketing and labeling		
417-1	Requirements for product and service information and labeling	Ethical Marketing
417-2	Incidents of non-compliance concerning product and service information and labeling	Performance Data
417-3	Incidents of non-compliance concerning marketing communications	Performance Data

The United Nations Sustainable Development Goals

CATALYST PHARMACEUTICALS UNSDG INDEX

United Nations Sustainable Development Goal ("UN SDG") Alignment

Good Health and Well-Being: By providing patients with innovative medicines and unmatched patient care, Catalyst enhances the lives of patients suffering from rare and difficult-to-treat diseases, often without any therapeutic options. In 2023, we added two new products to our portfolio, FYCOMPA® and AGAMREE®, which provide relief to patients suffering from seizures and DMD, respectively. As we expand our product portfolio, we are committed to upholding Catalyst's values of providing patients with safe, accessible, and affordable medication, all of which contribute to our ability to enhance the health and well-being of patients in need.

Quality Education: Catalyst is committed to ensuring employees have the appropriate resources and support to excel in their careers. As part of Catalyst's commitment to our employees, we provide education benefits and tuition reimbursement which can be used for graduate degree programs. These programs increase accessibility to continuing education for our employees while also contributing our ability to develop top-tier talent at our Company.

Gender Equality: Catalyst promotes equal opportunities within our Company and prohibits discriminatory practices, prejudice, and harassment of any kind. As part of our commitment to creating an inclusive workplace, we have programs in place to empower women to thrive in our workforce.

Decent Work and Economic Growth: As part of our efforts to recruit and retain a skilled workforce, Catalyst provides competitive compensation plans and top-tier employee benefits. In addition to compensation packages, Catalyst provides employees with resources, such as tuition reimbursement and continued training, to develop their skills and enhance their professional growth.

Industry, Innovation and Infrastructure: In 2023, Catalyst expanded and diversified our product portfolio to include two additional innovative products that help address unmet medical needs. Catalyst is dedicated to delivering innovative medicines to make a meaningful difference for patients living with rare and other difficult-to-treat diseases, and we will continue to invest in unique and clinically differentiated opportunities in order to serve more patients.

The United Nations Sustainable Development Goals

CATALYST PHARMACEUTICALS UNSDG INDEX

United Nations Sustainable Development Goal ("UN SDG") Alignment

Reduced Inequalities: As Catalyst expands its product portfolio, we remain committed to reducing inequalities through access to healthcare and community engagement initiatives. We spearhead various internal initiatives, such as our expanded access programs and Catalyst Pathways, to enhance patients' abilities to access the medication they need. We also demonstrate our commitment to reducing inequalities in the community with donations of time and money to organizations that benefit the healthcare community.

Climate Action: As our business expands, we continue to explore ways in which we can understand and minimize our carbon footprint. We are actively taking steps to measure and track our GHG emissions, water consumption, and waste generation. By understanding our impact, we can actively identify opportunities to reduce our footprint.

Peace, Justice, and Strong Institutions: As outlined in various Company policies, Catalyst is dedicated to fulfilling our core values of Passion, Trust, and Integrity in every aspect of our business. We expect our employees, vendors, and business partners to do the same by conducting business in an ethical manner.

Partnerships for the Goals: Catalyst partners with various organizations aimed at developing safe and affordable medicines for patients in need. Through collaboration with industry associations and charitable organizations, we demonstrate our commitment to advance product quality, patient safety, and access to healthcare. As we expand our business, we will continue to pursue opportunities to collaborate with organizations that help us reach our goals and fulfill our mission.


Catalyst
pharmaceuticals